Agilent (A) 10-K20 Dec 222022 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Oct. 31, 2022	Dec. 09, 2022	Apr. 30, 2022
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Oct. 31, 2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--10-31
Document Fiscal Year Focus	2022
Document Transition Report	false
Entity File Number	001-15405
Entity Registrant Name	Agilent Technologies, Inc.
Entity Central Index Key	0001090872
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0518772
Entity Address, Address Line One	5301 Stevens Creek Blvd.
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95051
City Area Code	(800)
Local Phone Number	227-9770
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	A
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 26,600
Entity Common Stock, Shares Outstanding		296,072,040
Amendment Flag	false
Documents Incorporated by Reference [Text Block]	Portions of the Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") to be held on March 15, 2023, and to be filed pursuant to Regulation 14A within 120 days after registrant's fiscal year ended October 31, 2022 are incorporated by reference into Part III of this Report

Audit Information

Audit Information	12 Months Ended
Audit Information	Oct. 31, 2022
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	San Jose, California
Auditor Firm ID	238

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Net revenue:
Net revenue	$ 6,848	$ 6,319	$ 5,339
Costs and expenses:
Cost of revenue	3,126	2,912	2,502
Research and development	467	441	495
Selling, general and administrative	1,637	1,619	1,496
Total costs and expenses	5,230	4,972	4,493
Income from operations	1,618	1,347	846
Interest income	9	2	8
Interest expense	(84)	(81)	(78)
Other income (expense), net	(39)	92	66
Income before taxes	1,504	1,360	842
Provision for income taxes	250	150	123
Net Income	$ 1,254	$ 1,210	$ 719
Net income per share:
Net income per share - basic	$ 4.19	$ 3.98	$ 2.33
Net income per share - diluted	$ 4.18	$ 3.94	$ 2.30
Weighted Averge Shares Used In Computing Net Income Per Share
Basic (in shares)	299	304	309
Diluted (in shares)	300	307	312
Products
Net revenue:
Net revenue	$ 5,187	$ 4,756	$ 3,993
Costs and expenses:
Cost of revenue	2,242	2,078	1,796
Services and Other
Net revenue:
Net revenue	1,661	1,563	1,346
Costs and expenses:
Cost of revenue	$ 884	$ 834	$ 706

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Statement of Comprehensive Income [Abstract]
Net Income	$ 1,254	$ 1,210	$ 719
Gain (loss) on derivative instruments, net of tax expense (benefit) of $13, $1 and $(3)	43	1	(9)
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $(8), $4 and $0	(26)	13	2
Other comprehensive income (loss):
Foreign currency translation, net of tax expense (benefit) of $(12), $2 and $1	(150)	9	10
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense (benefit) of $9, $74 and $0	69	218	(5)
Change in net prior service benefit, net of tax benefit of $0, $0 and $(1)	(1)	(1)	(6)
Other Comprehensive Income (Loss)	(65)	240	(8)
Total comprehensive income	$ 1,189	$ 1,450	$ 711

CONSOLIDATED STATEMENT OF COM_2

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Gain (loss) on derivatives, tax expense (benefit)	$ 13	$ 1	$ (3)
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit)	(8)	4	0
Foreign currency translation, tax expense (benefit)	(12)	2	1
Change in actuarial net loss, tax expense (benefit)	9	74	0
Change in net prior service benefit, tax (benefit)	0	0	(1)
Total comprehensive income	$ 1,189	$ 1,450	$ 711

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,053	$ 1,484
Short-term Investments	0	91
Accounts receivable, net	1,405	1,172
Inventory	1,038	830
Other current assets	282	222
Total current assets	3,778	3,799
Property, plant and equipment, net	1,100	945
Goodwill	3,952	3,975
Other intangible assets, net	821	981
Long-term investments	195	185
Other assets	686	820
Total assets	10,532	10,705
Current liabilities:
Accounts payable	580	446
Employee compensation and benefits	455	493
Deferred revenue	461	441
Short-term debt	36	0
Other accrued liabilities	329	328
Total current liabilities	1,861	1,708
Long-Term Debt	2,733	2,729
Retirement and post-retirement benefits	97	220
Other long-term liabilities	536	659
Total liabilities	5,227	5,316
Commitments and contingencies (Note 12 and 16)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 295 million shares at October 31, 2022 and 302 million shares at October 31, 2021 issued and outstanding	3	3
Additional paid-in-capital	5,325	5,320
Retained earnings	324	348
Accumulated other comprehensive loss	(347)	(282)
Total stockholders' equity	5,305	5,389
Total liabilities and equity	$ 10,532	$ 10,705

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares shares in Thousands	Oct. 31, 2022	Oct. 31, 2021
Stockholders' equity:
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock shares authorized (in shares)	125,000	125,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock shares authorized (in shares)	2,000,000	2,000,000
Common stock issued (in shares)	295,000	302,000
Common stock outstanding	295,000	302,000

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Cash flows from operating activities:
Net Income	$ 1,254	$ 1,210	$ 719
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	317	321	308
Share-based compensation	125	110	83
Deferred taxes	8	14	29
Excess and obsolete inventory related charges	24	29	28
Asset impairment charges	0	2	99
Change in fair value of contingent consideration	(25)	(21)	0
Net (gain) loss on equity securities	(67)	98	27
Loss on extinguishment of debt	9	17	0
Other non-cash expense, net	11	3	8
Changes in assets and liabilities:
Accounts receivable, net	(321)	(128)	(107)
Inventory	(248)	(136)	(68)
Accounts payable	121	64	2
Employee compensation and benefits	(22)	112	29
Other assets and liabilities	(8)	(14)	(182)
Net cash provided by operating activities	1,312	1,485	921
Cash flows from investing activities:
Investments in property, plant and equipment	(291)	(188)	(119)
Proceeds from the sale of property, plant and equipment	0	1	1
Proceeds from the sale of equity securities	22	12	0
Payments to acquire equity securities	(13)	(22)	(20)
Payment in exchange for convertible note	(4)	(5)	(9)
Acquisitions of businesses and intangible assets, net of cash acquired	(52)	(547)	0
Net cash used in investing activities	(338)	(749)	(147)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	58	55	60
Payment of taxes related to net share settlement of equity awards	(67)	(76)	(37)
Treasury stock repurchases	(1,139)	(788)	(469)
Payment of dividends	(250)	(236)	(222)
Issuance of senior notes and long-term loan	600	848	499
Debt issuance costs	0	(7)	(4)
Repayment of Senior notes	(609)	(417)	0
Proceeds from commercial paper	1,295	1,647	420
Repayments of commercial paper	(1,260)	(1,722)	(345)
Repayments of finance leases	0	0	(4)
Proceeds from credit facility and short-term loan	0	0	798
Repayments of debt and revolving credit facility	0	0	(1,413)
Net cash used in financing activities	(1,372)	(696)	(717)
Effect of exchange rate movements	(36)	3	2
Net increase (decrease) in cash, cash equivalents and restricted cash	(434)	43	59
Cash, cash equivalents and restricted cash at beginning of year	1,490	1,447	1,388
Cash, cash equivalents and restricted cash at end of year	1,056	1,490	1,447
Supplemental Cash Flow Information [Abstract]
Income Taxes Payments, Net	279	211	361
Interest payments	85	76	71
Property, Plant and Equipment
Supplemental Cash Flow Information [Abstract]
Net change in property, plant and equipment included in accounts payable and accrued liabilities-increase (decrease)	$ 26	$ 27	$ (1)

CONSOLIDATED STATEMENT OF EQUIT

CONSOLIDATED STATEMENT OF EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Loss	Total Stockholders Equity
Components of comprehensive income, net of tax:
Total stockholders' equity		$ 3	$ 5,277	$ (18)	$ (514)	$ 4,748
Balance (in shares) at Oct. 31, 2019		309,071
Components of comprehensive income, net of tax:
Net Income	$ 719			719		719
Other comprehensive income (loss)	(8)				(8)	(8)
Total comprehensive income	711					711
Cash dividends declared	(222)			(222)		(222)
Shares-based awards issued, Net of tax (Shares)		2,354
Share-based awards issued, Net of tax (Value)			22			22
Stock Repurchased and Retired During Period, Shares		(5,227)
Stock Repurchased and Retired During Period, Value		$ 0	(71)	(398)		(469)
Share-based compensation			83			83
Balance (in shares) at Oct. 31, 2020		306,198
Components of comprehensive income, net of tax:
Total stockholders' equity		$ 3	5,311	81	(522)	4,873
Net Income	1,210			1,210		1,210
Other comprehensive income (loss)	240				240	240
Total comprehensive income	1,450					1,450
Cash dividends declared	(236)			(236)		(236)
Shares-based awards issued, Net of tax (Shares)		2,083
Share-based awards issued, Net of tax (Value)			(20)			(20)
Stock Repurchased and Retired During Period, Shares		(6,073)
Stock Repurchased and Retired During Period, Value		$ 0	(81)	(707)		(788)
Share-based compensation			110			110
Balance (in shares) at Oct. 31, 2021		302,208
Components of comprehensive income, net of tax:
Total stockholders' equity	5,389	$ 3	5,320	348	(282)	5,389
Net Income	1,254			1,254		1,254
Other comprehensive income (loss)	(65)				(65)	(65)
Total comprehensive income	1,189					1,189
Cash dividends declared	(250)			(250)		(250)
Shares-based awards issued, Net of tax (Shares)		1,419
Share-based awards issued, Net of tax (Value)			(9)			(9)
Stock Repurchased and Retired During Period, Shares		(8,368)
Stock Repurchased and Retired During Period, Value		$ 0	(111)	(1,028)		(1,139)
Share-based compensation			125			125
Balance (in shares) at Oct. 31, 2022		295,259
Components of comprehensive income, net of tax:
Total stockholders' equity	$ 5,305	$ 3	$ 5,325	$ 324	$ (347)	$ 5,305

CONSOLIDATED STATEMENT OF EQU_2

CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Statement of Stockholders' Equity [Abstract]
Payment, Tax Withholding, Share-based Payment Arrangement	$ 67	$ 76	$ 37
Cash Dividends Declared (per common share)	$ 0.840	$ 0.776	$ 0.720

OVERVIEW AND SUMMARY OF SIGNIFI

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Oct. 31, 2022
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. New Segment Structure. In the first quarter of fiscal year 2022, we announced a change in organizational structure designed to enable our growth strategies and strengthen our focus on customers. Our chemistries and supplies business and our remarketed instruments business moved from our Agilent CrossLab business segment to our life sciences and applied markets business segment. We also moved BioTek's service revenue and related cost of sales from our life sciences and applied markets business segment to our Agilent CrossLab business segment. Following this reorganization, we continue to have three business segments (life sciences and applied markets, diagnostics and genomics and Agilent CrossLab), each of which continues to comprise a reportable segment. We began reporting under this new structure with the Quarterly Report on Form 10-Q for the period ended January 31, 2022. Historical financial segment information has been recast to conform to this new presentation in our financial statements and accompanying notes. There was no change to our diagnostics and genomics business segment. Basis of Presentation. The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year. Principles of Consolidation. The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of Estimates. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes. Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others. Both our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) and the resulting volatility and uncertainty it has caused in the U.S. and international markets. The global supply chain and logistics pressures, high inflation, and COVID-related shutdowns in China have made it more challenging for companies to manage operations. We cannot provide any assurances that any prolonged material disruptions in the supply chain will not have a material impact on our consolidated financial statements. As of October 31, 2022, our consolidated financial statements have not been materially impacted. Revenue Recognition. We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time. We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers , (“ASC 606’’). See also Note 3, "Revenue" for additional information on revenue recognition. Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. For products that transfer control over time, revenue is recognized as the performance obligation is satisfied. Product over time revenue is assessed against the following criteria: the performance creates an asset that the customer controls as the asset is created; the asset has no alternative use; and we have an enforceable right to payment. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded. Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed. We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis. Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations. A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases beginning in 2020 and ASC 840, Leases for prior periods. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. Deferred Revenue. Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Sales Taxes. Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue. Shipping and Handling Costs. Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented. Research and Development. Costs related to research, design and development of our products are charged to research and development expense as they are incurred. Advertising. Advertising costs are generally expensed as incurred and amounted to $66 million in 2022, $63 million in 2021 and $48 million in 2020. Taxes on Income. Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 5, "Income Taxes" for more information. Net Income Per Share. Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 6, "Net Income Per Share". Cash, Cash Equivalents and Short-Term Investments. We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. As of October 31, 2022, approximately $1,028 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds. We classify equity investments as short-term investments based on their nature and our intent and ability to exit within a year or less. As of October 31, 2022, we had no short-term investments. Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows: October 31, 2022 2021 2020 (in millions) Cash and cash equivalents $ 1,053 $ 1,484 $ 1,441 Restricted cash included in other assets 3 6 6 Total cash, cash equivalents and restricted cash $ 1,056 $ 1,490 $ 1,447 Accounts Receivable, net. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2022 and 2021 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material. Concentration of Credit Risk. Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, equity investments with readily determinable fair value securities, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents or short-term investments. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2022, or 2021. Inventory. Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory. Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets. Capitalized Software. We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete. Leases. We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component. A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard. See also Note 9, "Leases" for additional information about our leases. Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life. Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates. Goodwill and Purchased Intangible Assets. We assess our goodwill and purchased intangible assets for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Under the authoritative guidance, we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the quantitative test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, then we are required to perform a quantitative impairment test on goodwill to identify and measure the amount of a goodwill impairment loss to be recognized. A goodwill impairment loss, if any, is measured as the amount by which a reporting unit's carrying value, including goodwill, exceeds its fair value, not to exceed the carrying amount of goodwill. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2022, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a quantitative test for goodwill impairment of the three reporting units as of November 1, 2021, due to the change in our segment structure. As of November 1, 2021, there was no impairment of goodwill. We also performed a qualitative test for goodwill impairment of the three reporting units as of September 30, 2022, our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2022, 2021 and 2020. Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2022. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets is indicated. During the year ended October 31, 2022 and 2021 there were no impairments of indefinite-lived intangible assets. During the year ended October 31, 2020, we recorded an impairment of in-process research and development of $90 million related to the shutdown of our sequencer development program in our diagnostics and genomics segment. Impairment of Long-Lived Assets. We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2022, there were no impairments of other long-lived assets or intangible assets. During the year ended October 31, 2021, we recorded an impairment charge of long-lived assets of $2 million. During the year ended October 31, 2020 we recorded an impairment charge of long-lived assets including indefinite-lived in-process research and development of $ 98 million Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2022 and 2021, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of October 31, 2022 and 2021, the total carrying value of investments and loans in privately held companies considered as VIEs was $87 million and $76 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the consolidated balance sheet. Investments. Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of marketable equity securities which were reclassified from non-marketable equity securities following the commencement of public market trading of the issuers and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. There are no equity investments with readily determinable fair value at October 31, 2022 and $91 million at October 31, 2021 . Other investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Trading securities, which are comprised of mutual funds, bonds and other similar instruments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2022 and 2021. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of short-term and long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not read

NEW ACCOUNTING PRONOUNCEMENTS

NEW ACCOUNTING PRONOUNCEMENTS	12 Months Ended
NEW ACCOUNTING PRONOUNCEMENTS	Oct. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	NEW ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Pronouncements In January 2020, accounting guidance was issued that clarifies the accounting guidance for equity method investments, joint ventures, and derivatives and hedging. The guidance clarifies the interaction between different sections of the accounting guidance that could be applicable and helps clarify which guidance should be applied in certain situations which increases relevance and comparability of financial statement information. On November 1, 2021, we adopted this guidance which did not have a material impact on our consolidated financial statements and disclosures. In October 2021, the FASB issued an update to improve the accounting for acquired revenue contracts with customers in a business combination. The amendments require an acquirer to use the guidance in ASC 606, Revenue from Contracts with Customers, rather than using fair value, when recognizing and measuring contract assets and contract liabilities related to customer contracts assumed in a business combination. On November 1, 2021 we early adopted this guidance which did not have a material impact on our consolidated financial statements and disclosures. New Accounting Pronouncements Not Yet Adopted In November 2021, the FASB issued updates to increase the transparency in the annual disclosure requirements relating to government assistance received by business entities in Topic 832, Government Assistance. The guidance requires certain disclosures about transactions with a government that are accounted for by applying a grant or contribution model. These amendments are effective for us beginning November 1, 2022, and for interim periods within that year. We do not expect that the adoption of this standard will have a material impact on our consolidated financial statements and disclosures. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

REVENUE (Notes)

REVENUE (Notes)	12 Months Ended
REVENUE (Notes)	Oct. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer	REVENUE The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Year Ended October 31, 2022: Americas $ 1,331 $ 567 $ 784 $ 2,682 Europe 907 382 410 1,699 Asia Pacific 1,769 503 195 2,467 Total $ 4,007 $ 1,452 $ 1,389 $ 6,848 Year Ended October 31, 2021: Americas $ 1,199 $ 510 $ 695 $ 2,404 Europe 893 378 417 1,688 Asia Pacific 1,571 472 184 2,227 Total $ 3,663 $ 1,360 $ 1,296 $ 6,319 Year Ended October 31, 2020: Americas $ 1,002 $ 449 $ 517 $ 1,968 Europe 746 326 371 1,443 Asia Pacific 1,367 402 159 1,928 Total $ 3,115 $ 1,177 $ 1,047 $ 5,339 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Years Ended October 31, 2022 2021 2020 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 2,515 2,224 $ 1,754 Chemicals and Advanced Materials 1,521 1,328 1,154 Diagnostics and Clinical 963 938 787 Food 617 601 517 Academia and Government 576 576 526 Environmental and Forensics 656 652 601 Total $ 6,848 $ 6,319 $ 5,339 Revenue by Type Instrumentation $ 2,907 2,657 $ 2,249 Non-instrumentation and other 3,941 3,662 3,090 Total $ 6,848 $ 6,319 $ 5,339 Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services. Contract Balances Contract Assets Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balances of contract assets as of October 31, 2022 and 2021, were $275 million and $197 million, respectively. Contract Liabilities The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2021 and 2022: Contract (in millions) Ending balance as of October 31, 2020 $ 446 Net revenue deferred in the period 406 Revenue recognized that was included in the contract liability balance at the beginning of the period (359) Change in deferrals from customer cash advances, net of revenue recognized 24 Currency translation and other adjustments 2 Ending balance as of October 31, 2021 $ 519 Net revenue deferred in the period 437 Revenue recognized that was included in the contract liability balance at the beginning of the period (372) Change in deferrals from customer cash advances, net of revenue recognized 11 Currency translation and other adjustments (38) Ending balance as of October 31, 2022 $ 557 Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Contract Costs Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The changes in total capitalized costs to obtain a contract were immaterial during the years ended October 31, 2022 and 2021 and are included in other current and long-term assets on the consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities. Transaction Price Allocated to the Remaining Performance Obligations We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
SHARE-BASED COMPENSATION	Oct. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, employee stock options, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan ("LTPP") based on estimated fair values. Description of Share-Based Plans Employee Stock Purchase Plan. Effective May 1, 2020, we adopted the 2020 Employee Stock Purchase Plan ("ESPP") which replaced our previous Employee Stock Purchase Plan. The ESPP allows eligible employees to contribute up to 10 percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. There are 31 million shares authorized for issuance in connection with the ESPP. Under our ESPP, employees purchased 469,701 shares for $54 million in 2022, 462,237 shares for $46 million in 2021 and 628,644 shares for $41 million in 2020. As of October 31, 2022, the number of shares of common stock authorized and available for issuance under our ESPP was 24,859,446. This excludes the number of shares of common stock to be issued to participants in consideration of the aggregate participant contributions totaling $27 million as of October 31, 2022. Incentive Compensation Plans. On November 15, 2017 and March 21, 2018, the Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2018 Stock Plan (the "2018 Plan") which amends, including renaming and extending the term of, the Agilent Technologies, Inc. 2009 Stock Plan (the "2009 Plan"). The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards. The 2018 Plan has a term of ten years. As of October 31, 2022, 21,496,468 shares were available for future awards under the 2018 Plan. Stock Options. In fiscal year 2021, we resumed granting stock options. Stock options granted under the 2018 Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. We issue new shares of common stock when employee stock options are exercised. Performance Shares. We have two LTPP performance stock award programs, which are administered under the 2018 Stock Plan, for our executive officers and other key employees. Participants in our LTPP Total Stockholders’ Return (“TSR”) and LTPP Earnings Per Share (“EPS”) programs are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets for the programs are met. The LTPP-TSR awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the TSR set at the beginning of the performance period. The LTPP-EPS awards are based on the company’s EPS performance over a three-year period. The performance targets for the LTPP-EPS for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards are subject to a one-year post-vest holding period. The final LTPP award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under the LTPP program is three years. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted Stock Units. We also issue restricted stock units under our share-based plans. The estimated fair value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. All restricted stock units granted to our executives after November 1, 2015, are subject to a one-year post-vest holding period. Impact of Share-based Compensation Awards We have recognized compensation expense based on the estimated grant date fair value method under the authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-line amortization method. As the guidance requires that share-based compensation expense should be based on awards that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated forfeitures. The impact on our results for share-based compensation was as follows: Years Ended October 31, 2022 2021 2020 (in millions) Cost of products and services $ 30 $ 26 $ 21 Research and development 14 12 9 Selling, general and administrative 82 73 54 Total share-based compensation expense $ 126 $ 111 $ 84 At October 31, 2022 and 2021, no share-based compensation was capitalized within inventory. Valuation Assumptions The fair value of share-based awards for our employee stock option awards was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value. We use historical volatility to estimate the expected stock price volatility assumption for employee stock option awards. In reaching the conclusion, we have considered many factors including the extent to which our options are currently traded and our ability to find traded options in the current market with similar terms and prices to the options we are valuing. In estimating the expected life of our options granted, we considered the historical option exercise behavior of our executives, which we believe is representative of future behavior. The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of our common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period. All LTPP awards granted to our senior management employees have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employees were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulation model and an expected dividend yield to compute the discount. The following assumptions were used to estimate the fair value of awards granted. Years Ended October 31, 2022 2021 2020 Stock Option Plan: Weighted average risk-free interest rate 1.5% 0.5% — Dividend yield 0.5% 0.7% — Weighted average volatility 26% 26% — Expected life 5.5 years 5.5 years — LTPP: Volatility of Agilent shares 29% 30% 23% Volatility of selected peer-company shares 23%-81% 24%-57% 15%-44% Pair-wise correlation with selected peers 41% 45% 29% Post-vest restriction discount for all executive awards 6.5% 6.8% 5.3% Share-Based Payment Award Activity Employee Stock Options The following table summarizes employee stock option award activity of our employees and directors for 2022. Options Weighted (in thousands) Outstanding at October 31, 2021 943 $ 69 Granted 279 $ 158 Exercised (108) $ 38 Cancelled (17) $ 130 Outstanding at October 31, 2022 1,097 $ 94 The options outstanding and exercisable for equity share-based payment awards at October 31, 2022 were as follows: Options Outstanding Options Exercisable Range of Number Weighted Weighted Aggregate Number Weighted Weighted Aggregate (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) $25.00 - $40.00 69 1.0 $ 38 $ 6,958 69 1.0 $ 38 $ 6,958 $40.01 - $50.00 386 2.0 $ 41 37,556 386 2.0 $ 41 37,556 $100.00- $110.00 325 8.0 $ 110 9,254 90 8.0 $ 110 2,555 $110.01 - $150.00 65 8.9 $ 128 687 9 8.5 $ 127 99 $150.01 & Over 252 9.0 $ 161 — 6 9.0 $ 159 — 1,097 5.8 $ 94 $ 54,455 560 3.1 $ 54 $ 47,168 The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $138.35 at October 31, 2022, which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-money awards exercisable at October 31, 2022 was approximately 0.6 million. The following table summarizes the aggregate intrinsic value of options exercised in 2022, 2021 and 2020 and the fair value of options granted in 2022: Aggregate Weighted Per Share Value Using Black-Scholes Model (in thousands) Options exercised in fiscal 2020 $ 30,481 $ 34 Options exercised in fiscal 2021 $ 34,305 $ 33 Black Scholes per share value of options granted during fiscal 2021 $ 26 Options exercised in fiscal 2022 $ 10,765 $ 38 Black Scholes per share value of options granted during fiscal 2022 $ 39 As of October 31, 2022, the unrecognized share-based compensation cost for outstanding stock option awards, net of expected forfeitures, was $8 million. The amount of cash received from the exercise of share-based awards granted was $58 million in 2022, $55 million in 2021 and $60 million in 2020. Non-Vested Awards The following table summarizes non-vested award activity in 2022 primarily for our LTPP and restricted stock unit awards. Shares Weighted (in thousands) Non-vested at October 31, 2021 2,519 $ 88 Granted 696 $ 155 Vested (1,189) $ 75 Forfeited (112) $ 114 Change in LTPP shares in the year due to exceeding performance targets 189 $ 65 Non-vested at October 31, 2022 2,103 $ 114 As of October 31, 2022, the unrecognized share-based compensation cost for non-vested restricted stock awards net of expected forfeitures was approximately $115 million which is expected to be amortized over a weighted average period of 2.1 years. The total fair value of restricted stock awards vested was $89 million for 2022, $84 million for 2021 and $85 million for 2020.

INCOME TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Oct. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The domestic and foreign components of income before taxes are: Years Ended October 31, 2022 2021 2020 (in millions) U.S. operations $ 858 $ 876 $ 54 Non-U.S. operations 646 484 788 Total income before taxes $ 1,504 $ 1,360 $ 842 The provision for income taxes is comprised of: Years Ended October 31, 2022 2021 2020 (in millions) U.S. federal taxes: Current $ 173 $ 122 $ 5 Deferred (28) (1) 4 Non-U.S. taxes: Current 47 (3) 84 Deferred 35 14 24 State taxes, net of federal benefit: Current 22 17 5 Deferred 1 1 1 Total provision for income taxes $ 250 $ 150 $ 123 The differences between the U.S. federal statutory income tax rate and our effective tax rate are: Years Ended October 31, 2022 2021 2020 (in millions) Profit before tax times statutory rate $ 316 $ 286 $ 177 State income taxes, net of federal benefit 23 18 6 Non-U.S. income taxed at different rates (18) 5 (37) Change in unrecognized tax benefits (6) (84) (8) Foreign-derived intangible income deduction (46) (35) (9) Excess tax benefits from stock-based compensation (19) (29) (18) Other, net — (11) 12 Provision (benefit) for income taxes $ 250 $ 150 $ 123 Effective tax rate 16.6 % 11.0 % 14.6 % For 2022, our income tax expense was $250 million with an effective tax rate of 16.6 percent. For the year ended October 31, 2022, our effective tax rate and the resulting provision for income taxes were impacted by the tax benefit of $46 million related to foreign-derived intangible income. For 2021, our income tax expense was $150 million with an effective tax rate of 11 percent. For the year ended October 31, 2021, our effective tax rate and the resulting provision for income taxes were impacted by the discrete benefit of $93 million related to the release of tax reserves in various jurisdictions due to audit settlements and the expiration of statutes of limitations. The income taxes for the year ended October 31, 2021 also include the excess tax benefits from stock-based compensation of $29 million. For 2020, our income tax expense was $123 million with an effective tax rate of 14.6 percent. For the year ended October 31, 2020, our effective tax rate and the resulting provision for income taxes were impacted by foreign income taxed at lower rates. We have negotiated a tax holiday in Singapore. The tax holiday provides a lower rate of taxation on certain classes of income and requires various thresholds of investments and employment or specific types of income. In December 2018, the tax holiday in Singapore was renegotiated and extended through 2027. As a result of the incentive, the impact of the tax holiday decreased income taxes by $53 million, $35 million, and $71 million in 2022, 2021, and 2020, respectively. The benefit of the tax holiday on net income per share (diluted) was approximately $0.18, $0.11, and $0.23 in 2022, 2021 and 2020, respectively. The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are: Years Ended October 31, 2022 2021 (in millions) Deferred Tax Assets Intangibles $ 62 $ 72 Employee benefits, other than retirement 45 43 Net operating loss, capital loss, and credit carryforwards 157 191 Share-based compensation 23 22 Lease obligations 29 30 Other 58 42 Deferred tax assets $ 374 $ 400 Tax valuation allowance (115) (120) Deferred tax assets, net of valuation allowance $ 259 $ 280 Deferred Tax Liabilities Property, plant and equipment $ (11) $ (11) Pension benefits and retiree medical benefits (24) (8) Right-of-use asset (29) (29) Other (7) (26) Deferred tax liabilities $ (71) $ (74) Net deferred tax assets (liabilities) $ 188 $ 206 Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2022, we continued to maintain a valuation allowance of $115 million until sufficient positive evidence exists to support reversal. The valuation allowance is primarily related to deferred tax assets for the states of California and Colorado, along with the net operating losses in the Netherlands and capital losses in Australia. At October 31, 2022, we had federal, state and foreign net operating loss carryforwards of approximately $6 million, $207 million and $384 million, respectively. The federal and state net operating loss carryforwards are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax laws. If not utilized, the federal and state net operating loss carryforwards will begin to expire in 2023. If not utilized, $3 million of the foreign net operating loss carryforwards will begin to expire in 2023. The remaining $381 million of the foreign net operating losses carry forward indefinitely. At October 31, 2022, we had foreign capital loss carryforwards of $108 million. The foreign capital losses carry forward indefinitely. At October 31, 2022, we had state tax credit carryforwards of approximately $87 million. The state tax credits carry forward indefinitely. The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows: October 31, 2022 2021 (in millions) Long-term deferred tax assets (included within other assets) $ 246 $ 309 Long-term deferred tax liabilities (included within other long-term liabilities) (58) (103) Total $ 188 $ 206 The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows: October 31, 2022 2021 (in millions) Current income tax assets (included within other current assets) $ 87 $ 66 Long-term income tax assets (included within other assets) 11 6 Current income tax liabilities (included within other accrued liabilities) (51) (47) Long-term income tax liabilities (included within other long-term liabilities) (216) (241) Total $ (169) $ (216) Uncertain Tax Positions The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows: 2022 2021 2020 (in millions) Balance, beginning of year $ 133 $ 195 $ 206 Additions for tax positions related to the current year 5 6 6 Additions for tax positions from prior years — 4 — Reductions for tax positions from prior years (9) — — Settlements with taxing authorities — (30) — Statute of limitations expirations (6) (42) (17) Balance, end of year $ 123 $ 133 $ 195 As of October 31, 2022, we had $144 million of unrecognized tax benefits, including interest and penalties of which $121 million, if recognized, would affect our effective tax rate. However, approximately $23 million of the unrecognized tax benefits were related to state income tax positions that, if recognized, would be in the form of a deferred tax asset that would likely not affect our effective tax rate due to a valuation allowance. We recognized tax benefit of $2 million in 2022, tax benefit of $19 million in 2021, and tax expense of $8 million in 2020, for interest and penalties related to unrecognized tax benefits. Interest and penalties accrued as of October 31, 2022 and 2021 were $21 million and $26 million, respectively. In the U.S., tax years remain open back to the year 2018 for federal income tax purposes and for significant states. In other major jurisdictions where we conduct business, the tax years generally remain open back to the year 2012. With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
NET INCOME (LOSS) PER SHARE	Oct. 31, 2022
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER SHARE	NET INCOME PER SHARE The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. Years Ended October 31, 2022 2021 2020 (in millions) Numerator: Net income $ 1,254 $ 1,210 $ 719 Denominators: Basic weighted average shares 299 304 309 Potential common shares — stock options and other employee stock plans 1 3 3 Diluted weighted average shares 300 307 312 The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive. In 2022, 2021 and 2020, we issued share-based awards of approximately 1.4 million, 2.1 million and 2.4 million, respectively. For the years ended 2022, 2021 and 2020, the impacts of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share were not material.

INVENTORY

INVENTORY	12 Months Ended
INVENTORY	Oct. 31, 2022
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY Inventory as of October 31, 2022 and 2021 consisted of the following: October 31, 2022 2021 (in millions) Finished goods $ 555 $ 463 Purchased parts and fabricated assemblies 483 367 Inventory $ 1,038 $ 830 Inventory-related excess and obsolescence charges of $24 million were recorded in cost of products in 2022, $29 million in 2021 and $28 million in 2020. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET	Oct. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment as of October 31, 2022 and 2021, consisted of the following: October 31, 2022 2021 (in millions) Land $ 59 $ 61 Buildings and leasehold improvements 1,255 1,147 Machinery and equipment 674 638 Software 260 221 Total property, plant and equipment 2,248 2,067 Accumulated depreciation and amortization (1,148) (1,122) Property, plant and equipment, net $ 1,100 $ 945 There were no asset impairments in 2022. During 2021 and 2020 we recorded asset impairments of $2 million and $6 million, respectively. In 2020 asset impairments related to the shutdown of our sequencer development program. Depreciation expenses were $120 million in 2022, $122 million in 2021 and $119 million in 2020. In 2022 and 2021 we retired approximately $48 million and $35 million, respectively, of assets, the majority of which were fully depreciated and no longer in use.

LEASES

LEASES	12 Months Ended
LEASES	Oct. 31, 2022
Leases [Abstract]
Lessee, Operating Leases	LEASES As a lessee, we have various non-cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years. The components of lease cost for operating leases were as follows: Year Ended October 31, 2022 2021 2020 (in millions) Operating lease cost $ 59 $ 59 $ 60 Short-term lease cost 2 2 1 Variable lease cost (a) 15 14 14 Sublease income (14) (13) (14) Total lease cost $ 62 62 61 (a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes. Supplemental cash flow information related to leases was as follows: Year Ended October 31, 2022 2021 2020 (in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 53 $ 57 $ 59 Non-cash right of use assets obtained in exchange for operating lease obligations $ 38 $ 53 $ 37 Supplemental balance sheet information related to leases was as follows: October 31, Financial Statement Line Item 2022 2021 (in millions, except lease term and discount rate) Assets: Operating lease: Right of use asset Other assets $ 150 $ 178 Liabilities: Current Operating lease liabilities Other accrued liabilities $ 51 $ 52 Long-term Operating lease liabilities Other long-term liabilities $ 101 $ 130 Weighted average remaining lease term (in years) Operating leases 7.4 years 7.6 years Weighted average discount rate Operating leases 2.4 % 1.9 % Future minimum rents payable as of October 31, 2022 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows: Operating Leases (in millions) 2023 $ 53 2024 36 2025 20 2026 11 2027 7 Thereafter 40 Total undiscounted future minimum lease payments $ 167 Less: amount of lease payments representing interest (15) Present value of future minimum lease payments $ 152 Less: current liabilities (51) Long-term lease liabilities $ 101 As of October 31, 2022, we had no additional significant operating or finance leases that had not yet commenced. As a lessor, we have contracts for equipment leased to customers primarily in connection with our diagnostics business which include both operating-type lease and sales-type finance lease arrangements. We account for the non-lease component under the revenue recognition ASC 606 guidance and the lease component under the leasing ASC 842 guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease. The cost of customer leased equipment is recorded within property, plant and equipment, and is netted in the consolidated balance sheet with depreciation over the equipment’s estimated useful life. For an arrangement that has been classified as a sales-type lease, revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment lease recorded which is calculated at the present value of the remaining lease payments due from the lessee. Revenue allocated to the lease income for both sales-type finance lease and operating lease rental arrangements represents less than one percent of total net revenue in the years ended October 31, 2022, 2021 and 2020, respectively. As of October 31, 2022, the original cost and net book value of operating leased assets were $29 million and $4 million, respectively. As of October 31, 2022, lease receivables related to sales-type leases were $38 million. As of October 31, 2021,

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS	Oct. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2021 and 2022: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2020 $ 1,738 $ 1,599 $ 265 $ 3,602 Foreign currency translation impact 5 — 3 8 Goodwill arising from acquisitions and adjustments — 365 — 365 Goodwill as of October 31, 2021 $ 1,743 $ 1,964 $ 268 $ 3,975 Foreign currency translation impact (19) (11) (12) (42) Goodwill arising from acquisitions and adjustments 19 — — 19 Goodwill as of October 31, 2022 $ 1,743 $ 1,953 $ 256 $ 3,952 In the first quarter of fiscal year 2022, we reorganized our operating segments and moved our chemistries and supplies business and our remarketed instruments business from our Agilent CrossLab business segment to our life sciences and applied markets business segment. As a result, we reassigned approximately $307 million of goodwill from our Agilent Crosslab business segment to our life sciences and applied markets business segment using the relative fair value allocation approach. In addition, we moved service revenue and cost of sales related to the previous acquisition of BioTek from our life sciences and applied markets business segment to our Agilent CrossLab business segment. As a result, we reassigned approximately $10 million of goodwill from our life sciences and applied markets segment to our Agilent Crosslab business segment using the relative fair value allocation approach. Goodwill balances as of October 31, 2020, have been recast to conform to this new presentation. There were no changes to our reporting units due to this reorganization. In addition, we performed a goodwill impairment test, and the results of the analysis indicated that the fair values for all three of our reporting units were in excess of their carrying values by substantial amounts; therefore, no impairment was indicated. As of September 30, 2022, our annual impairment test date, we assessed goodwill for triggering events and circumstances, and determined no impairment of goodwill was indicated for our reporting units. The component parts of other intangible assets at October 31, 2021 and 2022 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2021: Purchased technology $ 1,742 $ 972 $ 770 Backlog 8 3 5 Trademark/Tradename 196 133 63 Customer relationships 357 228 129 Third-party technology and licenses 11 8 3 Total amortizable intangible assets $ 2,314 $ 1,344 $ 970 In-Process R&D 11 — 11 Total $ 2,325 $ 1,344 $ 981 As of October 31, 2022: Purchased technology $ 1,733 $ 1,068 $ 665 Backlog 8 8 — Trademark/Tradename 196 148 48 Customer relationships 180 105 75 Third-party technology and licenses 32 9 23 Total amortizable intangible assets $ 2,149 $ 1,338 $ 811 In-Process R&D 10 — 10 Total $ 2,159 $ 1,338 $ 821 In 2022, we acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization for $41 million. During fiscal year 2022, we recorded additions to goodwill of $19 million and additions to other intangible assets of $35 million related to the acquisition of PSS and advanced artificial intelligence technology. During the year other intangible assets decreased $3 million due to the impact of foreign currency translation. In 2021, we acquired privately-owned Resolution Bioscience, Inc., a biotechnology company focused on the development and commercialization of next-generation sequencing-based ("NGS") precision oncology solutions, for $561 million cash plus potential future contingent payments of up to $145 million upon the achievement of certain milestones. See also Note 12, "Fair Value Measurements" for additional information. During fiscal year 2021, we recorded additions to goodwill of $365 million and additions to other intangible assets of $343 million related to this acquisition. During the year, other intangible assets increased $2 million due to the impact of foreign currency translation. In general, for United States federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible. There were no impairments of indefinite-lived intangible assets during fiscal years 2022 and 2021. During fiscal year 2020, we recorded an impairment of in-process research and development of $ 90 million Amortization expense of intangible assets was $192 million in 2022, $195 million in 2021, and $186 million in 2020. Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) 2023 $ 145 2024 $ 126 2025 $ 102 2026 $ 72 2027 $ 71 Thereafter $ 295

INVESTMENTS

INVESTMENTS	12 Months Ended
INVESTMENTS	Oct. 31, 2022
Schedule of Investments [Abstract]
Investment Holdings, Schedule of Investments	INVESTMENTS The following table summarizes the company's equity investments as of October 31, 2022 and 2021 (net book value): October 31, 2022 2021 (in millions) Short-Term Equity investments - with readily determinable fair value $ — 91 Long-Term Equity investments - without readily determinable fair value $ 141 $ 120 Equity investments - with readily determinable fair value 23 31 Trading securities 31 34 Total long-term investments $ 195 $ 185 Equity investments without readily determinable fair value (RDFV) consist of non-marketable equity securities issued by private companies. These investments are accounted for using the measurement alternative at cost adjusting for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer). The adjustments are included in net income in the period in which they occur. Equity investments with RDFV consist of marketable equity securities which are publicly traded and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Other investments with RDFV consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Our investments without RDFV and marketable equity securities with RDFV are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have a significant adverse effect on the future value of the investment. Gains and losses reflected in other income (expense), net for our equity investments with RDFV and equity investments without RDFV are summarized below: Years Ended October 31, 2022 2021 2020 ( in millions) Net gain (loss) recognized during the period on equity securities $ (67) $ 98 $ 27 Less: Net gain on equity securities sold during the period 11 6 — Unrealized gain (loss) on equity securities held as of the end of the period $ (78) $ 92 $ 27 Unrealized gains on our equity securities without RDFV were $6 million, $17 million and $27 million in 2022, 2021 and 2020, respectively. In 2022, net unrealized losses on our trading securities were $7 million. In 2021 and 2020, net unrealized gains on our trading securities were $8 million and $2 million, respectively. There were no impairments of investments in 2022, 2021 and 2020.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Oct. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 — applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 — applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 — applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 were as follows: Fair Value Measurement October 31, Quoted Prices Significant Significant (in millions) Assets: Short-term Cash equivalents (money market funds) $ 492 $ 492 $ — $ — Derivative instruments (foreign exchange contracts) 31 — 31 — Long-term Trading securities 31 31 — — Other investments 23 — 23 — Total assets measured at fair value $ 577 $ 523 $ 54 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Contingent consideration 66 — — 66 Long-term Deferred compensation liability 31 — 31 — Contingent consideration 1 — — 1 Total liabilities measured at fair value $ 103 $ — $ 36 $ 67 Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2021 were as follows: Fair Value Measurement October 31, Quoted Prices Significant Significant (in millions) Assets: Short-term Cash equivalents (money market funds) $ 919 $ 919 $ — $ — Derivative instruments (foreign exchange contracts) 9 — 9 — Short-term investments - Equity securities with RDFV 91 83 8 — Long-term Trading securities 34 34 — — Other investments 31 — 31 — Total assets measured at fair value $ 1,084 $ 1,036 $ 48 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Contingent consideration 62 — — 62 Long-term Deferred compensation liability 34 — 34 — Contingent consideration 27 — — 27 Total liabilities measured at fair value $ 128 $ — $ 39 $ 89 Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Short-term investments - equity securities with readily determinable fair value ("RDFV") are shares in marketable equity securities which are classified as Level 1 in the fair value hierarchy as they are measured based on quotes in active markets. Equity securities with RDFV also includes potential shares received from an equity investment in a company that went public and can vest under certain stock performance circumstances. These have been classified as Level 2 because the fair value was calculated using the Monte Carlo simulation method in which quoted market price and other observable inputs are used. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. These shares have been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself. Contingent Consideration. The fair value of the contingent consideration liability relates to milestone payments in connection with the acquisition of advanced artificial intelligence technology in February 2022 and the acquisition of Resolution Bioscience in April 2021. Resolution Bioscience. The fair value of the potential future milestone payments, which is set to certain revenue and technical targets, was based on (i) the probability of achieving the relevant revenue targets and technical milestones and (ii) the timing of achieving such milestones, which are significant unobservable inputs, and has been classified as Level 3. We used the Monte Carlo simulation approach to estimate the fair value of the revenue component. The fair value of the revenue component was zero at October 31, 2022. The probability-weighted expected return method was used to estimate the fair value of the technical target component. Assumptions used in the calculations include probability of success, duration of the earn-out and discount rate. A change in any of these unobservable inputs can significantly change the fair value of the contingent consideration. As of October 31, 2022, the expected maximum earn-out period for the contingent payments does not exceed 2.2 years and potential future payments will not exceed $145 million. The contingent consideration liability is our only Level 3 asset or liability. A summary of the Level 3 activity follows: Contingent Consideration (in millions) Balance at October 31, 2020 $ — Additions to contingent consideration (including measurement period adjustment) 110 Change in fair value (included within selling, general and administrative expenses) (21) Balance at October 31, 2021 $ 89 Additions to contingent consideration 3 Change in fair value (included within selling, general and administrative expenses) (25) Balance at October 31, 2022 67 The fair value of the contingent consideration liability as of October 31, 2022 was estimated to be $67 million of which $66 million was recorded in other accrued liabilities and $1 million was recorded in other long-term liabilities on the consolidated balance sheet. The net decrease in the fair value of the contingent consideration was primarily driven by a change in the probability of achieving the relevant revenue targets. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-Lived Assets For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2022, 2021 and 2020: Years Ended 2022 2021 2020 (in millions) Long-lived assets held and used $ — $ 2 $ 98 Long-lived assets held for sale $ — $ — $ — For the year ended October 31, 2022, there were no impairments of long-lived assets held and used. For the year ended October 31, 2021, long-lived assets held and used with a carrying value of $2 million were written down to their fair value of zero, resulting in an impairment of $2 million. For the year ended October 31, 2020, long-lived assets held and used, including indefinite lived in-process research and development intangible assets, with a carrying amount of $98 million were written down to their fair value of zero, resulting in an impairment charge of $98 million related to the shutdown of our sequencer development program and other assets in our diagnostics and genomics segment. There were no impairments of long-lived assets held for sale in 2022, 2021 and 2020. Fair values for the impaired long-lived assets during 2020 were measured using level 3 inputs. To determine the fair value of long-lived assets in 2020, we used the income approach based on projected discounted cash flows expected to be generated by the long-lived assets over the remaining useful life. Non-Marketable Equity Securities For the years ended October 31, 2022, 2021 and 2020, there were no impairments in non-marketable securities without readily determinable fair value. For the years ended October 31, 2022, 2021 and 2020, unrealized gains of $6 million, $17 million and $27 million respectively, were included in net income as an adjustment to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of October 31, 2022, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of a $35 million gain and no losses, and the carrying amount was $141 million. As of October 31, 2021, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of a $29 million gain and no losses, and the carrying amount was $120 million. Fair values for the non-marketable securities included in long-term investments on the consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when they occur.

DERIVATIVES

DERIVATIVES	12 Months Ended
DERIVATIVES	Oct. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts and purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of October 31, 2022, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the years ended October 31, 2022, 2021 and 2020, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant. In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2022 was $4 million. In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2022 was $4 million. Net Investment Hedges We enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss)- translation adjustment and are assessed for effectiveness against the underlying exposure every reporting period. If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period. For the year ended October 31, 2022, ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant. Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of October 31, 2022, was $1 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of October 31, 2022. There were 270 foreign exchange forward contracts open as of October 31, 2022, and designated as cash flow hedges. There were 190 foreign exchange forward contracts open as of October 31, 2022, not designated as hedging instruments. There were 3 foreign exchange forward contracts open as of October 31, 2022, and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of October 31, 2022 were as follows: Derivatives Designated as Derivatives Designated as Derivatives Forward Forward Forward Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (78) $ (10) $ (18) British Pound (66) — 13 Canadian Dollar (55) — (17) Japanese Yen (93) — (42) Danish Krone — — 25 Korean Won (90) — (10) Singapore Dollar 19 — 24 Swiss Franc — — (13) Chinese Yuan Renminbi (87) — (100) Taiwan Dollar — — (16) India Rupee — — (11) Other 4 — 3 $ (446) $ (10) $ (162) Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2022 and 2021 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location October 31, October 31, Balance Sheet Location October 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 23 $ 6 Other accrued liabilities $ 2 $ 2 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 8 $ 3 Other accrued liabilities $ 3 $ 3 Total derivatives $ 31 $ 9 $ 5 $ 5 The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Years Ended October 31, 2022 2021 2020 (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts: Loss reclassified from accumulated other comprehensive income (loss) into interest expense $ (2) $ (1) $ (1) Gain (loss) recognized in accumulated other comprehensive income (loss) $ 56 $ 2 $ (12) Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ 36 $ (16) $ (1) Gain on time value of forward contracts recorded in cost of sales $ — $ — $ 2 Net investment hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) - translation adjustment $ 5 $ 1 $ (5) Gain on time value of forward contracts recorded in other income (expense) — 1 — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense), net $ 10 $ — $ (1) At October 31, 2022 the total amount of existing net gain that is expected to be reclassified from accumulated other comprehensive income (loss) is $24 million. Within the next twelve months it is estimated that $20 million of gain included within the net amount of accumulated other comprehensive income (loss) will be reclassified to cost of sales in respect of cash flow hedges.

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	12 Months Ended
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	Oct. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS General. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Agilent provides defined benefits to U.S. employees who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the "RP"). Effective November 1, 2014, Agilent’s U.S. RP was closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. As of April 30, 2016, benefits under the RP were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016, remained fully vested and is payable on termination, retirement, death, or permanent disability, based on an eligible participant’s years of credited service, age and other criteria. There are no additional benefit accruals after April 30, 2016. For eligible service through October 31, 1993, the benefit payable under the Agilent Retirement Plan is reduced by any amounts due to the eligible employee under the Agilent defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was closed to new participants as of November 1993. As of October 31, 2022 and 2021, the fair value of plan assets of the DPSP was $93 million and $136 million, respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets. Agilent also maintains a Supplemental Benefits Retirement Plan ("SBRP") in the U.S., which is a supplemental unfunded non-qualified defined benefit plan to provide benefits that would be provided under the RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans" in the tables below. Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements. Post-Retirement Medical Benefit Plans. In addition to receiving retirement benefits, Agilent U.S. employees who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc. Health Plan for Retirees. As of January 1, 2020, the Health Plan for Retirees is comprised solely of insured pre-65 HMOs as the self-funded Pre-Medicare Medical Plan was eliminated effective December 31, 2019. The Health Plan for Retirees was closed to new retiree entrants after December 31, 2020. If eligible, a retiree may receive a fixed amount (different fixed amounts for different groups) under the Retiree Medical Account (“RMA”) or a fixed monthly amount under the Agilent Reimbursement Arrangement (“ARA”). Any new employee hired on or after November 1, 2014, will not be eligible to participate in the post-retirement medical benefit plans upon retiring. 401(k) Defined Contribution Plan . Eligible Agilent U.S. employees may participate in the Agilent Technologies, Inc. 401(k) Plan. We match contributions to employees up to a maximum of 6 percent of an employee's annual eligible compensation. Effective May 1, 2016 until April 30, 2022, we provided an additional transitional company contribution for certain eligible employees equal to 3 percent, 4 percent or 5 percent of an employee's annual eligible compensation due to the RP benefits being frozen. The maximum employee contribution to the 401(k) Plan is 50 percent of an employee's annual eligible compensation, subject to regulatory limitations. The 401(k) Plan employer expense included in income from operations was $46 million in 2022, $43 million in 2021 and $41 million in 2020. Components of Net periodic cost. The service cost component is recorded in cost of sales and operating expenses in the consolidated statement of operations. All other cost components are recorded in other income (expense), net in the consolidated statement of operations. The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future lifetime of participants using the corridor method. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for each year's gains and losses. For the years ended October 31, 2022, 2021 and 2020, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: Pensions U.S. Post-Retirement Benefit Plans U.S. Plans Non-U.S. Plans 2022 2021 2020 2022 2021 2020 2022 2021 2020 (in millions) Net periodic benefit cost (benefit) Service cost — benefits earned during the period $ — $ — $ — $ 22 $ 22 $ 24 $ 1 $ 1 $ 1 Interest cost on benefit obligation 14 14 15 9 8 8 2 2 3 Expected return on plan assets (27) (29) (28) (43) (49) (47) (6) (6) (7) Amortization of net actuarial (gain) loss — 4 3 25 53 49 (2) 4 4 Amortization of prior service benefit — — — — — — (1) (1) (7) Total periodic benefit cost (benefit) $ (13) $ (11) $ (10) $ 13 $ 34 $ 34 $ (6) $ — $ (6) Settlement loss $ 4 $ 1 $ 4 $ — $ — $ — $ — $ — $ — Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Net actuarial (gain) loss $ 16 $ (92) $ 26 $ (83) $ (114) $ 20 $ 15 $ (30) $ 5 Amortization of net actuarial (gain) loss — (4) (3) (25) (53) (49) 2 (4) (4) Amortization of prior service benefit — — — — — — 1 1 7 Loss due to settlement (4) (1) (4) — — — — — — Foreign currency — — — 11 5 10 — — — Total recognized in other comprehensive (income) loss $ 12 $ (97) $ 19 $ (97) $ (162) $ (19) $ 18 $ (33) $ 8 Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 3 $ (107) $ 13 $ (84) $ (128) $ 15 $ 12 $ (33) $ 2 Funded Status. As of October 31, 2022 and 2021, the funded status of the defined benefit and post-retirement benefit plans was: U.S. Defined Non-U.S. Defined U.S. 2022 2021 2022 2021 2022 2021 (in millions) Change in fair value of plan assets: Fair value — beginning of year $ 551 $ 439 $ 1,093 $ 945 $ 116 $ 93 Actual return on plan assets (122) 138 (147) 160 (26) 28 Employer contributions — — 17 19 — — Participants' contributions — — 1 1 — — Benefits paid (10) (8) (35) (31) (5) (5) Settlements (23) (18) — — — — Currency impact — — (181) (1) — — Fair value — end of year $ 396 $ 551 $ 748 $ 1,093 $ 85 $ 116 Change in benefit obligation: Benefit obligation — beginning of year $ 512 $ 510 $ 1,100 $ 1,094 $ 84 $ 94 Service cost — — 22 22 1 1 Interest cost 14 14 9 8 2 2 Participants' contributions — — 1 1 — — Actuarial (gain) loss (133) 15 (262) 2 (17) (8) Benefits paid (10) (8) (35) (31) (5) (5) Settlements (26) (19) — — — — Currency impact — — (170) 4 — — Benefit obligation — end of year $ 357 $ 512 $ 665 $ 1,100 $ 65 $ 84 Overfunded (underfunded) status of PBO $ 39 $ 39 $ 83 $ (7) $ 20 $ 32 Amounts recognized in the consolidated balance sheet consist of: Other assets $ 42 $ 46 $ 140 $ 160 $ 20 $ 32 Employee compensation and benefits (1) (1) — — — — Retirement and post-retirement benefits (2) (6) (57) (167) — — Total net asset (liability) $ 39 $ 39 $ 83 $ (7) $ 20 $ 32 Amounts Recognized in Accumulated Other Comprehensive Income (Loss): Actuarial (gains) losses $ 48 $ 36 $ 52 $ 149 $ (6) $ (23) Prior service costs (benefits) — — — — (3) (4) Total $ 48 $ 36 $ 52 $ 149 $ (9) $ (27) The actuarial gains and losses related to the change in plan obligations were a total of $412 million net gain for 2022 and $9 million net loss for 2021. The actuarial net gain that arose in 2022 was primarily due to increases in discount rates and changes in other financial and demographic assumptions partially offset by losses due to plan experience. The actuarial net loss that arose in 2021 was primarily due to changes in financial and demographic assumptions and losses due to plan experience offset by increases in discount rates. Investment Policies and Strategies as of October 31, 2022 . In the U.S., target asset allocations for our retirement and post-retirement benefit plans were approximately 50 percent to equities and approximately 50 percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately 1 percent of the retirement and post-retirement plans consists of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S., our target asset allocation ranges from 15 percent to 60 percent to equities, from 30 percent to 80 percent to fixed income investments, from zero to 25 percent to real estate and from zero to 55 percent to annuity contracts, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity and bond markets, our actual allocations of plan assets at October 31, 2022, may differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation. Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Real estate securities include holdings of managed investment funds which invest primarily in the equity instruments of real estate investment trusts and other similar real estate investments. Other investments include a group trust consisting primarily of private equity partnerships. Portions of the cash and cash equivalent, equity, and fixed income investments are held in commingled funds that are valued using Net Asset Value (“NAV”) as the practical expedient. In addition, some of the investments valued using NAV as the practical expedient may have limits on their redemption to weekly or monthly and/or may require prior written notice specified by each fund. In December 2021, we entered into an insurance buy-in contract for a portion of benefit obligations under the U.K. defined benefit plan which was funded from existing pension plan assets with no adjustment made to the benefit obligations. It has been classified as an “Annuity Contract” since the insurance buy-in contract is similar to an annuity contract. It matches cash flows with future benefit payments for listed pensioners as of the contract date with the obligation remaining with the plan. This contract is issued by a third-party insurance company with no affiliation to us. Fair Value. The measurement of the fair value of pension and post-retirement plan assets uses the valuation methodologies and the inputs as described in Note 12, "Fair Value Measurements". Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds also invest in short-term domestic fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and quality. Some of our cash and cash equivalents are held in commingled funds. Other cash and cash equivalents are generally classified as Level 2 investments. Equity - Some equity securities consisting of common and preferred stock that are not traded on an active market are valued at quoted prices reported by investment dealers based on the underlying terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments. Fixed Income - Some of the fixed income securities are not actively traded and are valued at quoted prices based on the terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments. Real Estate - Real estate securities include holdings of managed investment funds which invest primarily in the equity instruments of real estate investment trust and other similar real estate investments. Since the existing securities have quoted prices in active markets, it has been classified as level 1 and grouped with equity. Annuity Contract – This consists of the U.K. insurance buy-in contract. Since it is valued on an insurer pricing basis, which reflects the purchase price adjusted for changes in discount rates and other actuarial assumptions which approximates fair value, it has been classified as level 3. Other Investments - Other investments also include partnership investments where, due to their private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners that manage the partnerships. These valuations are based on proprietary appraisals, application of public market multiples to private company cash flows, utilization of market transactions that provide valuation information for comparable companies and other methods. Holdings of limited partnerships are classified as Level 3. Agilent has adopted the accounting guidance related to the presentation of certain investments using the NAV practical expedient. The accounting guidance exempts investments using this practical expedient from categorization within the fair value hierarchy. The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2022 and 2021. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 1 $ — $ — $ — $ 1 Equity 194 49 — — 145 Fixed Income 199 — — — 199 Other Investments 2 — — 2 — Total assets measured at fair value $ 396 $ 49 $ — $ 2 $ 345 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 2 $ — $ — $ — $ 2 Equity 276 62 — — 214 Fixed Income 271 2 — — 269 Other Investments 2 — — 2 — Total assets measured at fair value $ 551 $ 64 $ — $ 2 $ 485 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2022 and 2021: Years Ended 2022 2021 Balance, beginning of year $ 2 $ 2 Realized gains/(losses) — 1 Unrealized gains/(losses) — — Purchases, sales, issuances, and settlements — (1) Transfers in (out) — — Balance, end of year $ 2 $ 2 The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2022 and 2021. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ — $ — $ — $ — $ — Equity 42 10 — — 32 Fixed Income 42 — — — 42 Other Investments 1 — — 1 — Total assets measured at fair value $ 85 $ 10 $ — $ 1 $ 74 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 3 $ — $ — $ — $ 3 Equity 55 13 — — 42 Fixed Income 57 — — — 57 Other Investments 1 — — 1 — Total assets measured at fair value $ 116 $ 13 $ — $ 1 $ 102 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2022 and 2021: Years Ended 2022 2021 Balance, beginning of year $ 1 $ 1 Realized gains/(losses) — 1 Unrealized gains/(losses) — — Purchases, sales, issuances, and settlements — (1) Transfers in (out) — — Balance, end of year $ 1 $ 1 The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2022 and 2021: Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 22 $ — $ 22 $ — $ — Equity 360 264 — — 96 Fixed Income 274 83 98 — 93 Annuity Contract 92 — — 92 — Total assets measured at fair value $ 748 $ 347 $ 120 $ 92 $ 189 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1)(2) (in millions) Cash and Cash Equivalents $ 25 $ — $ 24 $ — $ 1 Equity 543 380 12 — 151 Fixed Income 525 151 242 — 132 Total assets measured at fair value $ 1,093 $ 531 $ 278 $ — $ 284 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. (2) Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications have no effect on the previously reported financial statements and other notes to the financial statements. For non-U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2022 and 2021: Years Ended 2022 2021 Balance, beginning of year $ — $ — Realized gains/(losses) — — Unrealized gains/(losses) (39) — Purchases, sales, issuances, and settlements (5) — Transfers in (out) 159 — Currency impact (23) — Balance, end of year $ 92 $ — The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2022 or 2021. 2022 2021 Benefit Benefit Fair Value of Fair Value of PBO PBO (in millions) U.S. defined benefit plans where PBO exceeds the fair value of plan assets $ 3 $ — $ 7 $ — U.S. defined benefit plans where fair value of plan assets exceeds PBO 354 396 505 551 Total $ 357 $ 396 $ 512 $ 551 Non-U.S. defined benefit plans where PBO exceeds the fair value of plan assets $ 172 $ 114 $ 691 $ 524 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 493 634 409 569 Total $ 665 $ 748 $ 1,100 $ 1,093 ABO ABO U.S. defined benefit plans where ABO exceeds the fair value of plan assets $ 3 $ — $ 7 $ — U.S. defined benefit plans where the fair value of plan assets exceeds ABO 354 396 505 551 Total $ 357 $ 396 $ 512 $ 551 Non-U.S. defined benefit plans where ABO exceeds the fair value of plan assets $ 167 $ 114 $ 668 $ 524 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO 485 634 400 569 Total $ 652 $ 748 $ 1,068 $ 1,093 Contributions and Estimated Future Benefit Payments. During fiscal year 2023, we expect to make no contributions to the U.S. defined benefit plans and the Post-Retirement Medical Plans. We expect to contribute $16 million to plans outside the U.S. The following table presents expected future benefit payments for the next 10 years: U.S. Defined Non-U.S. Defined U.S. Post-Retirement (in millions) 2023 $ 31 $ 32 $ 6 2024 $ 34 $ 33 $ 6 2025 $ 32 $ 34 $ 7 2026 $ 32 $ 34 $ 7 2027 $ 32 $ 35 $ 7 2028 - 2032 $ 142 $ 187 $ 34 Assumptions. The assumptions used to determine the benefit obligations and net periodic cost (benefit) for our defined benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted) in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at which pension and post-retirement obligations could be settled based on the measurement dates of the plans - October 31. The U.S. discount rates at October 31, 2022 and 2021, were determined based on the results of matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments within various countries. Assumptions used to calculate the net periodic cost (benefit) in each year were as follows: For years ended October 31, 2022 2021 2020 U.S. defined benefit plans: Discount rate 2.75% 2.75% 3.25% Expected long-term return on assets 5.00% 7.00% 7.00% Non-U.S. defined benefit plans: Discount rate 0.29-1.76% 0.07-1.54% 0.22-1.81% Average increase in compensation levels 2.00-3.50% 2.00-3.00% 2.25-3.00% Expected long-term return on assets 2.75-5.50% 4.00-5.50% 4.00-5.75% Interest crediting rate for cash balance plans 0.30-0.50% 0.10-0.50% 0.00-0.75% U.S. post-retirement benefits plans: Discount rate 2.75% 2.50% 3.00% Expected long-term return on assets 5.00% 7.00% 7.00% Current medical cost trend rate 6.00% 6.25% 6.25% Ultimate medical cost trend rate 4.50% 4.50% 4.50% Medical cost trend rate decreases to ultimate rate in year 2027 2029 2029 Assumptions used to calculate the benefit obligation were as follows: As of the Years Ending October 31, 2022 2021 U.S. defined benefit plans: Discount rate 6.00% 2.75% Non-U.S. defined benefit plans: Discount rate 1.50-4.77% 0.29-1.76% Average increase in compensation levels 2.00-3.25% 2.00-3.50% Interest crediting rate for cash balance plans 0.50-2.10% 0.30-0.50% U.S. post-retirement benefits plans: Discount rate 6.00% 2.75% Current medical cost trend rate 7.00% 6.00% Ultimate medical cost trend rate 4.75% 4.50% Medical cost trend rate decreases to ultimate rate in year 2029 2027

GUARANTEES

GUARANTEES	12 Months Ended
GUARANTEES	Oct. 31, 2022
Guarantees [Abstract]
GUARANTEES	GUARANTEES Standard Warranty We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below. October 31, 2022 2021 (in millions) Standard warranty accrual, beginning balance $ 30 $ 32 Accruals for warranties including change in estimates 50 52 Settlements made during the period (50) (54) Standard warranty accrual, ending balance $ 30 $ 30 Accruals for warranties due within one year $ 30 $ 29 Accruals for warranties due after one year — 1 Standard warranty accrual, ending balance $ 30 $ 30 Bank Guarantees Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $37 million and $46 million as of October 31, 2022 and 2021, respectively. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss. Indemnifications in Connection with Transactions In connection with various divestitures, acquisitions, spin-offs and other transactions, we have agreed to indemnify certain parties, their affiliates and/or other related parties against certain damages and expenses that might occur in the future. These indemnifications may cover a variety of liabilities, including, but not limited to, employee, tax, environmental, intellectual property, litigation and other liabilities related to the business conducted prior to the date of the transaction. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2022. Indemnifications to Officers and Directors Our corporate bylaws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and each board-appointed officer of Agilent which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in the bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made payments related to these obligations, and the fair value for these indemnification obligations was not material as of October 31, 2022. Other Indemnifications As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as defense, settlement, or payment of judgment for intellectual property claims related to the use of our products. From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss, expense, or liability arising from various triggering events related to the sale and the use of our products and services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the assets and businesses that we sell and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time we also provide protection to these parties against claims related to undiscovered liabilities, additional product liability or environmental obligations. In our experience, claims made under such indemnifications are rare and the associated estimated fair value of the liability was not material as of October 31, 2022. In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such businesses, their respective affiliates and other related parties against certain damages that they might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2022.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Oct. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	16. COMMITMENTS AND CONTINGENCIES Other Purchase Commitments. Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, there are termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contract's termination period before such contract can be cancelled. Our contractual obligations with these suppliers under "other purchase commitments" were approximately $139 million. Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT

SHORT-TERM DEBT	12 Months Ended
SHORT-TERM DEBT	Oct. 31, 2022
Short-Term Debt [Abstract]
SHORT-TERM DEBT	SHORT-TERM DEBT Credit Facilities On March 13, 2019, we entered into a credit agreement with a group of financial institutions which, as amended, provides for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024, and incremental term loan facilities in an aggregate amount of up to $500 million. On April 21, 2021, we entered into an incremental assumption agreement, pursuant to which the aggregate amount available for borrowing under the revolving credit facility was increased to $1.35 billion and the aggregate amount available for incremental facilities was refreshed to remain at $500 million. As of both October 31, 2022 and 2021, we had no borrowings outstanding under the credit facility and we had no borrowings outstanding under the incremental facilities. We were in compliance with the covenants for the credit facility during the year ended October 31, 2022. Commercial Paper Under our U.S. commercial paper program, we may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.35 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. As of October 31, 2022 , we had borrowings of $35 million outstanding under our U.S. commercial paper program and had a weighted average annual interest rate of 3.54 percent. As of October 31, 2021, w e had no borrowings outstanding under the U.S. commercial paper program

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
LONG-TERM DEBT	Oct. 31, 2022
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT Term Loan Facility On April 15, 2022, we entered into a term loan agreement with a group of financial institutions, which provided for a $600 million delayed draw term loan that will mature on April 15, 2025. As of October 31, 2022, we had $600 million borrowings outstanding under the term loan facility and had a weighted average interest rate of 3.98 percent. Loans under the term loan agreement bear interest, at our option, either at: (i) the alternate base rate, as defined in the term loan agreement, plus the applicable margin for such loans or (ii) adjusted term SOFR, as defined in the term loan agreement, plus the applicable margin for such loans. The term loan agreement contains customary representations and warranties as well as customary affirmative and negative covenants. We were in compliance with the covenants for the term loan during the year ended October 31, 2022. Senior Notes The following table summarizes the company's long-term senior notes: October 31, 2022 October 31, 2021 Amortized Amortized (in millions) 2023 Senior Notes $ — $ 599 2026 Senior Notes 299 298 2029 Senior Notes 495 494 2030 Senior Notes 496 496 2031 Senior Notes 843 842 Total Senior Notes $ 2,133 $ 2,729 2023 Senior Notes On June 21, 2013, the company issued aggregate principal amount of $600 million in senior notes ("2023 senior notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes would have matured on July 15, 2023 with a fixed interest rate of 3.875% per annum. We paid interest semi-annually on January 15th and July 15th of each year and payments commenced January 15, 2014. On May 4, 2022, we used the proceeds from the term loan facility and repaid the $600 million outstanding aggregate principal amount of our 2023 senior notes. The total redemption price of approximately $609 million was computed in accordance with the terms of the 2023 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest on the notes being redeemed. In May 2022, we recorded a loss on extinguishment of debt of $9 million in other income (expense), net in the consolidated statement of operations. In addition, $7 million of accrued interest, up to but not including the applicable redemption date, was paid. 2026 Senior Notes On September 22, 2016, the company issued aggregate principal amount of $300 million in senior notes ("2026 senior notes"). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017. In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2022 was $4 million. 2029 Senior Notes On September 16, 2019, the company issued an aggregate principal amount of $500 million in senior notes ("2029 senior notes"). The 2029 senior notes were issued at 99.316% of their principal amount. The notes will mature on September 15, 2029, and bear interest at a fixed rate of 2.75% per annum. The interest is payable semi-annually on March 15th and September 15th of each year and payments commenced on March 15, 2020. In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2022 was $4 million. 2030 Senior Notes On June 4, 2020, we issued an aggregate principal amount of $500 million in senior notes ("2030 senior notes"). The 2030 senior notes were issued at 99.812% of their principal amount. The 2030 senior notes will mature on June 4, 2030, and bear interest at a fixed rate of 2.10% per annum. The interest is payable semi-annually on June 4th and December 4th of each year and payments commenced on December 4, 2020. 2031 Senior Notes On March 12, 2021, we issued an aggregate principal amount of $850 million in senior notes ("2031 senior notes"). The 2031 senior notes were issued at 99.822% of their principal amount. The 2031 senior notes will mature on March 12, 2031, and bear interest at a fixed rate of 2.30% per annum. The interest is payable semi-annually on March 12th and September 12th of each year and payments commenced on September 12, 2021. All outstanding senior notes listed above are unsecured and rank equally in right of payment with all of Agilent's other senior unsecured indebtedness.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
STOCKHOLDERS' EQUITY	Oct. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	STOCKHOLDERS' EQUITY Stock Repurchase Program On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 share repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2020, we repurchased and retired 5.2 million shares for $469 million under this authorization. During the year ended October 31, 2021, we repurchased and retired 3.1 million shares for $365 million under this authorization. Effective February 18, 2021, the 2019 repurchase program was terminated and replaced by the new share repurchase program. The remaining authorization under the 2019 repurchase plan of $193 million expired on February 18, 2021. On February 16, 2021 we announced that our board of directors had approved a new share repurchase program (the "2021 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2021 repurchase program authorizes the purchase of up to $2.0 billion of our common stock at the company's discretion and has no fixed termination date. The 2021 repurchase program which became effective on February 18, 2021, replaced and terminated the 2019 repurchase program on that date. The 2021 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2021, we repurchased and retired 3.0 million shares for $423 million under this authorization. During the year ended October 31, 2022, we repurchased and retired 8.4 million shares for $1,139 million under this authorization. As of October 31, 2022, we had remaining authorization to repurchase up to approximately $438 million of our common stock under the 2021 repurchase program. Cash Dividends on Shares of Common Stock During the year ended October 31, 2022, cash dividends of $0.840 per share, or $250 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2021, cash dividends of $0.776 per share, or $236 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2020, cash dividends of $0.720 per share, or $222 million were declared and paid on the company's outstanding common stock. On November 16, 2022, we declared a quarterly dividend of $0.225 per share of common stock, or approximately $66 million which will be paid on January 25, 2023, to shareholders of record as of the close of business on January 3, 2023. The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated Other Comprehensive Income (Loss) The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2022 and 2021, net of tax effect: October 31, 2022 2021 (in millions) Foreign currency translation, net of tax (expense) benefit of $4 and $(8) $ (335) (185) Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $71 and $80 (32) (100) Unrealized gains (losses) on derivative instruments, net of tax (expense) benefit of $(4) and $1 20 3 Total accumulated other comprehensive loss $ (347) $ (282) Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2022 and 2021 were as follows: Net defined benefit pension cost and post retirement plan costs Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2020 $ (194) $ 125 $ (442) $ (11) $ (522) Other comprehensive income before reclassifications 11 — 228 2 241 Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 64 17 80 Tax expense (2) — (74) (5) (81) Other comprehensive income (loss) 9 (1) 218 14 240 As of October 31, 2021 $ (185) $ 124 $ (224) $ 3 $ (282) Other comprehensive income (loss) before reclassifications (162) — 50 56 (56) Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 28 (34) (7) Tax (expense) benefit 12 — (9) (5) (2) Other comprehensive income (loss) (150) (1) 69 17 (65) As of October 31, 2022 $ (335) $ 123 $ (155) $ 20 $ (347) Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2022 and 2021 were as follows (in millions): Details about Accumulated Other Amounts Reclassified Affected line item in 2022 2021 Unrealized gains (losses) on derivatives $ 36 $ (16) Cost of products Unrealized gains (losses) on derivatives (2) (1) Interest expense 34 (17) Total before income tax (8) 4 (Provision) benefit for income tax 26 (13) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (28) (64) Other (income) expense Prior service benefit 1 1 Other (income) expense (27) (63) Total before income tax 7 15 Benefit for income tax (20) (48) Total net of income tax Total reclassifications for the period $ 6 $ (61) Amounts in parentheses indicate reductions to income and increases to other comprehensive income. Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 14, "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
SEGMENT INFORMATION	Oct. 31, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Description of Segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In the first quarter of fiscal year 2022, we announced a change in organizational structure designed to enable our growth strategies and strengthen our focus on customers. Our chemistries and supplies business and our remarketed instruments business moved from our Agilent CrossLab business segment to our life sciences and applied markets business segment. We also moved BioTek's service revenue and related cost of sales from our life sciences and applied markets business segment to our Agilent CrossLab business segment. The historical financial segment information has been recast to conform to this new presentation. There was no change to our diagnostics and genomics business segment. Following this reorganization, we continue to have three business segments comprised of life sciences and applied markets, diagnostics and genomics and Agilent CrossLab, each of which continues to comprise a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our consumables portfolio is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries to supplies. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business is a contract and development manufacturing organization that provides services related to and the production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in a class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential tissue and liquid-based pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business provides clinical flow cytometry reagents for routine cancer diagnostics. This business also provides bulk antibodies as raw materials and associated assay development services to IVD manufacturers, biotechnology and pharmaceutical companies. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples. Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques including NGS, utilized in clinical and life science research applications. The Agilent CrossLab business spans the entire lab with its extensive services portfolio, which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning we can serve and supply customers regardless of their instrument purchase choices. The services portfolio include repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the customers' laboratory operations. Custom services are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arises from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses, costs of centralized research and development and joint sales and marketing. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate asset impairments, amortization of acquisition-related intangible assets, change in the fair value of acquisition-related contingent consideration, acquisition and integration costs, transformational initiatives expenses, acceleration of share-based compensation expense related to workforce reduction, business exit and divestiture costs, special compliance costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding items such as asset impairment charges, transformational initiatives, acquisition and integration costs, non-cash amortization of intangible assets related to business combinations, interest income, interest expense, and other items as noted in the reconciliations below. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Year Ended October 31, 2022: Total net revenue $ 4,007 $ 1,389 $ 1,452 $ 6,848 Income from operations $ 1,186 $ 301 $ 370 $ 1,857 Depreciation expense $ 59 $ 39 $ 22 $ 120 Share-based compensation expense (1) $ 69 $ 25 $ 26 $ 120 Year Ended October 31, 2021: Total net revenue $ 3,663 $ 1,296 $ 1,360 $ 6,319 Income from operations $ 1,017 $ 273 $ 323 $ 1,613 Depreciation expense $ 60 $ 39 $ 23 $ 122 Share-based compensation expense (1) $ 60 $ 22 $ 24 $ 106 Year Ended October 31, 2020: Total net revenue $ 3,115 $ 1,047 $ 1,177 $ 5,339 Income from operations $ 792 $ 192 $ 272 $ 1,256 Depreciation expense $ 58 $ 39 $ 22 $ 119 Share-based compensation expense (1) $ 46 $ 17 $ 18 $ 81 (1) Share-based compensation expense in 2022, 2021 and 2020 excludes amounts not allocated to the segments related to accelerated share-based compensation expense from workforce reduction and from our acquisition of BioTek and Resolution Bioscience. The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes: Years Ended October 31, 2022 2021 2020 (in millions) Total reportable segments' income from operations $ 1,857 $ 1,613 $ 1,256 Amortization of intangible assets related to business combinations (191) (194) (184) Acquisition and integration costs (25) (41) (41) Transformational initiatives (30) (37) (53) Acceleration of share-based compensation expense related to workforce reduction — (1) (2) Asset impairments — (2) (99) Business exit and divestiture costs (7) (5) (2) Change in fair value of contingent consideration 25 21 — Special compliance costs — (1) — Other (1) (11) (6) (29) Interest Income 9 2 8 Interest Expense (84) (81) (78) Other income (expense), net (2) (39) 92 66 Income before taxes, as reported $ 1,504 $ 1,360 $ 842 (1) For the year ended October 31, 2020, the other category primarily includes legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments. (2) For the year ended October 31, 2022 and 2021, other income (expense), net includes net gains and losses on the fair value of equity securities. For the year ended October 31, 2020, other income (expense), net includes the settlement of a legal claim against Twist Bioscience Corporation. Major Customers. No customer represented 10 percent or more of our total net revenue in 2022, 2021 or 2020. The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of use assets and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) As of and for the Year Ended October 31, 2022: Assets $ 3,955 $ 3,489 $ 869 $ 8,313 Capital expenditures $ 77 $ 181 $ 33 $ 291 As of and for the Year Ended October 31, 2021: Assets $ 3,741 $ 3,320 $ 839 $ 7,900 Capital expenditures $ 64 $ 100 $ 24 $ 188 The following table reconciles segment assets to Agilent's total assets: October 31, 2022 2021 (in millions) Total reportable segments' assets $ 8,313 $ 7,900 Cash and cash equivalents 1,053 1,484 Short-term investments — 91 Prepaid expenses 119 91 Long-term investments 195 185 Long-term and other receivables 134 126 Deferred tax assets 246 309 Right of use assets 150 178 Other 322 341 Total assets $ 10,532 $ 10,705 The other category primarily includes over funded pension plans which are not allocated to the segments. The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location. United China (1) Rest of the Total (in millions) Net revenue: Year Ended October 31, 2022 $ 2,385 $ 1,499 $ 2,964 $ 6,848 Year Ended October 31, 2021 $ 2,159 $ 1,273 $ 2,887 $ 6,319 Year Ended October 31, 2020 $ 1,752 $ 1,087 $ 2,500 $ 5,339 1. China also includes Hong Kong net revenue. The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe. United Germany Rest of the Total (in millions) Long-lived assets: October 31, 2022 $ 1,080 $ 151 $ 492 $ 1,723 October 31, 2021 $ 912 $ 134 $ 587 $ 1,633

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
Schedule II Valuation and Qualifying Accounts	Oct. 31, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Column A Column B Column C Column D Column E Description Balance at Additions Charged to Deductions Credited to Expenses or Other Accounts** Balance at (in millions) 2022 Tax valuation allowance $ 120 $ 7 $ (12) $ 115 2021 Tax valuation allowance $ 132 $ 5 $ (17) $ 120 2020 Tax valuation allowance $ 134 $ 6 $ (8) $ 132 * Additions include current year additions charged to expenses and current year build due to increases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.

OVERVIEW AND SUMMARY OF SIGNI_2

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
Business Description and Basis of Presentation	Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. New Segment Structure. In the first quarter of fiscal year 2022, we announced a change in organizational structure designed to enable our growth strategies and strengthen our focus on customers. Our chemistries and supplies business and our remarketed instruments business moved from our Agilent CrossLab business segment to our life sciences and applied markets business segment. We also moved BioTek's service revenue and related cost of sales from our life sciences and applied markets business segment to our Agilent CrossLab business segment. Following this reorganization, we continue to have three business segments (life sciences and applied markets, diagnostics and genomics and Agilent CrossLab), each of which continues to comprise a reportable segment. We began reporting under this new structure with the Quarterly Report on Form 10-Q for the period ended January 31, 2022. Historical financial segment information has been recast to conform to this new presentation in our financial statements and accompanying notes. There was no change to our diagnostics and genomics business segment. Basis of Presentation. The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of Consolidation	Principles of Consolidation. The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes.
Risk and Uncertainties	Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.
Revenue Recognition	Revenue Recognition. We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time. We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers , (“ASC 606’’). See also Note 3, "Revenue" for additional information on revenue recognition. Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. For products that transfer control over time, revenue is recognized as the performance obligation is satisfied. Product over time revenue is assessed against the following criteria: the performance creates an asset that the customer controls as the asset is created; the asset has no alternative use; and we have an enforceable right to payment. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded. Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed. We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis. Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations. A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases beginning in 2020 and ASC 840, Leases for prior periods. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. Deferred Revenue. Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Sales Taxes. Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue. Shipping and Handling Costs. Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.
Research and Development	Research and Development. Costs related to research, design and development of our products are charged to research and development expense as they are incurred.
Advertising	Advertising. Advertising costs are generally expensed as incurred and amounted to $66 million in 2022, $63 million in 2021 and $48 million in 2020.
Taxes on Income	Taxes on Income. Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 5, "Income Taxes" for more information.
Net Income (Loss) Per Share	Net Income Per Share. Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 6, "Net Income Per Share".
Cash, Cash Equivalents and Short-Term Investments and Restricted Cash and Restricted Cash Equivalents	Cash, Cash Equivalents and Short-Term Investments. We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. As of October 31, 2022, approximately $1,028 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds. We classify equity investments as short-term investments based on their nature and our intent and ability to exit within a year or less. As of October 31, 2022, we had no short-term investments. Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows: October 31, 2022 2021 2020 (in millions) Cash and cash equivalents $ 1,053 $ 1,484 $ 1,441 Restricted cash included in other assets 3 6 6 Total cash, cash equivalents and restricted cash $ 1,056 $ 1,490 $ 1,447
Accounts Receivable, net	Accounts Receivable, net. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2022 and 2021 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.
Concentration of Credit Risk	Concentration of Credit Risk. Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, equity investments with readily determinable fair value securities, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents or short-term investments. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2022, or 2021.
Inventory	Inventory. Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.
Property, Plant and Equipment	Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.
Capitalized Software	Capitalized Software. We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.
Leases	Leases. We determine whether an arrangement is, or contains, a lease at inception. Prior to November 1, 2019, for leases where we are the lessee, we accounted for operating lease payments by charging them to expense as incurred. At the beginning of fiscal 2020, the company adopted new lease accounting guidance issued by the Financial Accounting Standards Board ("FASB"). The most significant change requires lessees to record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component. A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.
Acquisitions	Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.
Goodwill and Purchased Intangible Assets	Goodwill and Purchased Intangible Assets. We assess our goodwill and purchased intangible assets for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Under the authoritative guidance, we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the quantitative test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, then we are required to perform a quantitative impairment test on goodwill to identify and measure the amount of a goodwill impairment loss to be recognized. A goodwill impairment loss, if any, is measured as the amount by which a reporting unit's carrying value, including goodwill, exceeds its fair value, not to exceed the carrying amount of goodwill. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2022, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a quantitative test for goodwill impairment of the three reporting units as of November 1, 2021, due to the change in our segment structure. As of November 1, 2021, there was no impairment of goodwill. We also performed a qualitative test for goodwill impairment of the three reporting units as of September 30, 2022, our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2022, 2021 and 2020. Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets. We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2022, there were no impairments of other long-lived assets or intangible assets. During the year ended October 31, 2021, we recorded an impairment charge of long-lived assets of $2 million. During the year ended October 31, 2020 we recorded an impairment charge of long-lived assets including indefinite-lived in-process research and development of $ 98 million
Variable Interest Entity	Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2022 and 2021, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of October 31, 2022 and 2021, the total carrying value of investments and loans in privately held companies considered as VIEs was $87 million and $76 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the consolidated balance sheet.
Investments	Investments. Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of marketable equity securities which were reclassified from non-marketable equity securities following the commencement of public market trading of the issuers and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. There are no equity investments with readily determinable fair value at October 31, 2022 and $91 million at October 31, 2021 . Other investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Trading securities, which are comprised of mutual funds, bonds and other similar instruments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2022 and 2021. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of short-term and long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities
Warranty	Warranty. Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 15, "Guarantees".
Employee Compensation and Benefits	Employee Compensation and Benefits. Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $123 million and $129 million as of October 31, 2022, and 2021, respectively.
Retirement and Post-Retirement Plans	Retirement and Post-Retirement Plans. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 14, “Retirement plans and post-retirement pension plans” for additional information.
Retirement of Treasury Shares	Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.
Share-Based Compensation	Share-Based Compensation. For the years ended 2022, 2021 and 2020, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $126 million in 2022, $111 million in 2021 and $84 million in 2020. See Note 4, "Share-based Compensation" for additional information.
Derivative Instruments	Derivative Instruments. Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes. All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) - translation adjustment. Amounts associated with cash flow hedges are
Foreign Currency Translation	Foreign Currency Translation. We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.

OVERVIEW AND SUMMARY OF SIGNI_3

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
Restricted Cash and Cash Equivalents	Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows: October 31, 2022 2021 2020 (in millions) Cash and cash equivalents $ 1,053 $ 1,484 $ 1,441 Restricted cash included in other assets 3 6 6 Total cash, cash equivalents and restricted cash $ 1,056 $ 1,490 $ 1,447

REVENUE (Tables)

REVENUE (Tables)	12 Months Ended
REVENUE (Tables)	Oct. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Year Ended October 31, 2022: Americas $ 1,331 $ 567 $ 784 $ 2,682 Europe 907 382 410 1,699 Asia Pacific 1,769 503 195 2,467 Total $ 4,007 $ 1,452 $ 1,389 $ 6,848 Year Ended October 31, 2021: Americas $ 1,199 $ 510 $ 695 $ 2,404 Europe 893 378 417 1,688 Asia Pacific 1,571 472 184 2,227 Total $ 3,663 $ 1,360 $ 1,296 $ 6,319 Year Ended October 31, 2020: Americas $ 1,002 $ 449 $ 517 $ 1,968 Europe 746 326 371 1,443 Asia Pacific 1,367 402 159 1,928 Total $ 3,115 $ 1,177 $ 1,047 $ 5,339 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Years Ended October 31, 2022 2021 2020 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 2,515 2,224 $ 1,754 Chemicals and Advanced Materials 1,521 1,328 1,154 Diagnostics and Clinical 963 938 787 Food 617 601 517 Academia and Government 576 576 526 Environmental and Forensics 656 652 601 Total $ 6,848 $ 6,319 $ 5,339 Revenue by Type Instrumentation $ 2,907 2,657 $ 2,249 Non-instrumentation and other 3,941 3,662 3,090 Total $ 6,848 $ 6,319 $ 5,339
Contract with Customer, Asset and Liability	The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2021 and 2022: Contract (in millions) Ending balance as of October 31, 2020 $ 446 Net revenue deferred in the period 406 Revenue recognized that was included in the contract liability balance at the beginning of the period (359) Change in deferrals from customer cash advances, net of revenue recognized 24 Currency translation and other adjustments 2 Ending balance as of October 31, 2021 $ 519 Net revenue deferred in the period 437 Revenue recognized that was included in the contract liability balance at the beginning of the period (372) Change in deferrals from customer cash advances, net of revenue recognized 11 Currency translation and other adjustments (38) Ending balance as of October 31, 2022 $ 557

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
SHARE-BASED COMPENSATION (Tables)	Oct. 31, 2022
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Allocated Share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Years Ended October 31, 2022 2021 2020 (in millions) Cost of products and services $ 30 $ 26 $ 21 Research and development 14 12 9 Selling, general and administrative 82 73 54 Total share-based compensation expense $ 126 $ 111 $ 84
Share-based compensation arrangement by share-based payment award fair value assumptions and methodology schedule	The following assumptions were used to estimate the fair value of awards granted. Years Ended October 31, 2022 2021 2020 Stock Option Plan: Weighted average risk-free interest rate 1.5% 0.5% — Dividend yield 0.5% 0.7% — Weighted average volatility 26% 26% — Expected life 5.5 years 5.5 years — LTPP: Volatility of Agilent shares 29% 30% 23% Volatility of selected peer-company shares 23%-81% 24%-57% 15%-44% Pair-wise correlation with selected peers 41% 45% 29% Post-vest restriction discount for all executive awards 6.5% 6.8% 5.3%
Summary of stock option award activity	The following table summarizes employee stock option award activity of our employees and directors for 2022. Options Weighted (in thousands) Outstanding at October 31, 2021 943 $ 69 Granted 279 $ 158 Exercised (108) $ 38 Cancelled (17) $ 130 Outstanding at October 31, 2022 1,097 $ 94
Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range	The options outstanding and exercisable for equity share-based payment awards at October 31, 2022 were as follows: Options Outstanding Options Exercisable Range of Number Weighted Weighted Aggregate Number Weighted Weighted Aggregate (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) $25.00 - $40.00 69 1.0 $ 38 $ 6,958 69 1.0 $ 38 $ 6,958 $40.01 - $50.00 386 2.0 $ 41 37,556 386 2.0 $ 41 37,556 $100.00- $110.00 325 8.0 $ 110 9,254 90 8.0 $ 110 2,555 $110.01 - $150.00 65 8.9 $ 128 687 9 8.5 $ 127 99 $150.01 & Over 252 9.0 $ 161 — 6 9.0 $ 159 — 1,097 5.8 $ 94 $ 54,455 560 3.1 $ 54 $ 47,168
Schedule of intrinsic value of options exercised and the fair value of options granted	The following table summarizes the aggregate intrinsic value of options exercised in 2022, 2021 and 2020 and the fair value of options granted in 2022: Aggregate Weighted Per Share Value Using Black-Scholes Model (in thousands) Options exercised in fiscal 2020 $ 30,481 $ 34 Options exercised in fiscal 2021 $ 34,305 $ 33 Black Scholes per share value of options granted during fiscal 2021 $ 26 Options exercised in fiscal 2022 $ 10,765 $ 38 Black Scholes per share value of options granted during fiscal 2022 $ 39
Non-vested award activity disclosure	The following table summarizes non-vested award activity in 2022 primarily for our LTPP and restricted stock unit awards. Shares Weighted (in thousands) Non-vested at October 31, 2021 2,519 $ 88 Granted 696 $ 155 Vested (1,189) $ 75 Forfeited (112) $ 114 Change in LTPP shares in the year due to exceeding performance targets 189 $ 65 Non-vested at October 31, 2022 2,103 $ 114

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Oct. 31, 2022
Income Tax Disclosure [Abstract]
Domestic and Foreign Components of Income before Taxes	The domestic and foreign components of income before taxes are: Years Ended October 31, 2022 2021 2020 (in millions) U.S. operations $ 858 $ 876 $ 54 Non-U.S. operations 646 484 788 Total income before taxes $ 1,504 $ 1,360 $ 842
Provision for income taxes	The provision for income taxes is comprised of: Years Ended October 31, 2022 2021 2020 (in millions) U.S. federal taxes: Current $ 173 $ 122 $ 5 Deferred (28) (1) 4 Non-U.S. taxes: Current 47 (3) 84 Deferred 35 14 24 State taxes, net of federal benefit: Current 22 17 5 Deferred 1 1 1 Total provision for income taxes $ 250 $ 150 $ 123
Tax rate reconciliation, U.S. federal statutory rate to effective tax rate from operations	The differences between the U.S. federal statutory income tax rate and our effective tax rate are: Years Ended October 31, 2022 2021 2020 (in millions) Profit before tax times statutory rate $ 316 $ 286 $ 177 State income taxes, net of federal benefit 23 18 6 Non-U.S. income taxed at different rates (18) 5 (37) Change in unrecognized tax benefits (6) (84) (8) Foreign-derived intangible income deduction (46) (35) (9) Excess tax benefits from stock-based compensation (19) (29) (18) Other, net — (11) 12 Provision (benefit) for income taxes $ 250 $ 150 $ 123 Effective tax rate 16.6 % 11.0 % 14.6 %
Significant components of deferred tax assets and deferred tax liabilities	The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are: Years Ended October 31, 2022 2021 (in millions) Deferred Tax Assets Intangibles $ 62 $ 72 Employee benefits, other than retirement 45 43 Net operating loss, capital loss, and credit carryforwards 157 191 Share-based compensation 23 22 Lease obligations 29 30 Other 58 42 Deferred tax assets $ 374 $ 400 Tax valuation allowance (115) (120) Deferred tax assets, net of valuation allowance $ 259 $ 280 Deferred Tax Liabilities Property, plant and equipment $ (11) $ (11) Pension benefits and retiree medical benefits (24) (8) Right-of-use asset (29) (29) Other (7) (26) Deferred tax liabilities $ (71) $ (74) Net deferred tax assets (liabilities) $ 188 $ 206 The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows: October 31, 2022 2021 (in millions) Long-term deferred tax assets (included within other assets) $ 246 $ 309 Long-term deferred tax liabilities (included within other long-term liabilities) (58) (103) Total $ 188 $ 206
Current and Long Term Tax Assets and Liabilities [Table Text Block]	The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows: October 31, 2022 2021 (in millions) Current income tax assets (included within other current assets) $ 87 $ 66 Long-term income tax assets (included within other assets) 11 6 Current income tax liabilities (included within other accrued liabilities) (51) (47) Long-term income tax liabilities (included within other long-term liabilities) (216) (241) Total $ (169) $ (216)
Aggregate Changes in Gross Unrecognized Tax Benefits	The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows: 2022 2021 2020 (in millions) Balance, beginning of year $ 133 $ 195 $ 206 Additions for tax positions related to the current year 5 6 6 Additions for tax positions from prior years — 4 — Reductions for tax positions from prior years (9) — — Settlements with taxing authorities — (30) — Statute of limitations expirations (6) (42) (17) Balance, end of year $ 123 $ 133 $ 195

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
NET INCOME (LOSS) PER SHARE (Tables)	Oct. 31, 2022
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. Years Ended October 31, 2022 2021 2020 (in millions) Numerator: Net income $ 1,254 $ 1,210 $ 719 Denominators: Basic weighted average shares 299 304 309 Potential common shares — stock options and other employee stock plans 1 3 3 Diluted weighted average shares 300 307 312

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
INVENTORY (Tables)	Oct. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory as of October 31, 2022 and 2021 consisted of the following: October 31, 2022 2021 (in millions) Finished goods $ 555 $ 463 Purchased parts and fabricated assemblies 483 367 Inventory $ 1,038 $ 830

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	Oct. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment as of October 31, 2022 and 2021, consisted of the following: October 31, 2022 2021 (in millions) Land $ 59 $ 61 Buildings and leasehold improvements 1,255 1,147 Machinery and equipment 674 638 Software 260 221 Total property, plant and equipment 2,248 2,067 Accumulated depreciation and amortization (1,148) (1,122) Property, plant and equipment, net $ 1,100 $ 945

LEASES (Tables)

LEASES (Tables)	12 Months Ended
LEASES (Tables)	Oct. 31, 2022
Leases [Abstract]
Lease, Cost	The components of lease cost for operating leases were as follows: Year Ended October 31, 2022 2021 2020 (in millions) Operating lease cost $ 59 $ 59 $ 60 Short-term lease cost 2 2 1 Variable lease cost (a) 15 14 14 Sublease income (14) (13) (14) Total lease cost $ 62 62 61 (a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes. Supplemental cash flow information related to leases was as follows: Year Ended October 31, 2022 2021 2020 (in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 53 $ 57 $ 59 Non-cash right of use assets obtained in exchange for operating lease obligations $ 38 $ 53 $ 37
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was as follows: October 31, Financial Statement Line Item 2022 2021 (in millions, except lease term and discount rate) Assets: Operating lease: Right of use asset Other assets $ 150 $ 178 Liabilities: Current Operating lease liabilities Other accrued liabilities $ 51 $ 52 Long-term Operating lease liabilities Other long-term liabilities $ 101 $ 130 Weighted average remaining lease term (in years) Operating leases 7.4 years 7.6 years Weighted average discount rate Operating leases 2.4 % 1.9 %
Schedule of Future Minimum Rent Payments	Future minimum rents payable as of October 31, 2022 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows: Operating Leases (in millions) 2023 $ 53 2024 36 2025 20 2026 11 2027 7 Thereafter 40 Total undiscounted future minimum lease payments $ 167 Less: amount of lease payments representing interest (15) Present value of future minimum lease payments $ 152 Less: current liabilities (51) Long-term lease liabilities $ 101

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	Oct. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill balances and movements for each reportable segments during the period	The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2021 and 2022: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2020 $ 1,738 $ 1,599 $ 265 $ 3,602 Foreign currency translation impact 5 — 3 8 Goodwill arising from acquisitions and adjustments — 365 — 365 Goodwill as of October 31, 2021 $ 1,743 $ 1,964 $ 268 $ 3,975 Foreign currency translation impact (19) (11) (12) (42) Goodwill arising from acquisitions and adjustments 19 — — 19 Goodwill as of October 31, 2022 $ 1,743 $ 1,953 $ 256 $ 3,952
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	The component parts of other intangible assets at October 31, 2021 and 2022 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2021: Purchased technology $ 1,742 $ 972 $ 770 Backlog 8 3 5 Trademark/Tradename 196 133 63 Customer relationships 357 228 129 Third-party technology and licenses 11 8 3 Total amortizable intangible assets $ 2,314 $ 1,344 $ 970 In-Process R&D 11 — 11 Total $ 2,325 $ 1,344 $ 981 As of October 31, 2022: Purchased technology $ 1,733 $ 1,068 $ 665 Backlog 8 8 — Trademark/Tradename 196 148 48 Customer relationships 180 105 75 Third-party technology and licenses 32 9 23 Total amortizable intangible assets $ 2,149 $ 1,338 $ 811 In-Process R&D 10 — 10 Total $ 2,159 $ 1,338 $ 821
Future Amortization expense for the next five years and thereafter	Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) 2023 $ 145 2024 $ 126 2025 $ 102 2026 $ 72 2027 $ 71 Thereafter $ 295

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
INVESTMENTS (Tables)	Oct. 31, 2022
Schedule of Investments [Abstract]
Investment	The following table summarizes the company's equity investments as of October 31, 2022 and 2021 (net book value): October 31, 2022 2021 (in millions) Short-Term Equity investments - with readily determinable fair value $ — 91 Long-Term Equity investments - without readily determinable fair value $ 141 $ 120 Equity investments - with readily determinable fair value 23 31 Trading securities 31 34 Total long-term investments $ 195 $ 185
Gain (Loss) on Securities	Gains and losses reflected in other income (expense), net for our equity investments with RDFV and equity investments without RDFV are summarized below: Years Ended October 31, 2022 2021 2020 ( in millions) Net gain (loss) recognized during the period on equity securities $ (67) $ 98 $ 27 Less: Net gain on equity securities sold during the period 11 6 — Unrealized gain (loss) on equity securities held as of the end of the period $ (78) $ 92 $ 27

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Oct. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 were as follows: Fair Value Measurement October 31, Quoted Prices Significant Significant (in millions) Assets: Short-term Cash equivalents (money market funds) $ 492 $ 492 $ — $ — Derivative instruments (foreign exchange contracts) 31 — 31 — Long-term Trading securities 31 31 — — Other investments 23 — 23 — Total assets measured at fair value $ 577 $ 523 $ 54 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Contingent consideration 66 — — 66 Long-term Deferred compensation liability 31 — 31 — Contingent consideration 1 — — 1 Total liabilities measured at fair value $ 103 $ — $ 36 $ 67 Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2021 were as follows: Fair Value Measurement October 31, Quoted Prices Significant Significant (in millions) Assets: Short-term Cash equivalents (money market funds) $ 919 $ 919 $ — $ — Derivative instruments (foreign exchange contracts) 9 — 9 — Short-term investments - Equity securities with RDFV 91 83 8 — Long-term Trading securities 34 34 — — Other investments 31 — 31 — Total assets measured at fair value $ 1,084 $ 1,036 $ 48 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Contingent consideration 62 — — 62 Long-term Deferred compensation liability 34 — 34 — Contingent consideration 27 — — 27 Total liabilities measured at fair value $ 128 $ — $ 39 $ 89
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The contingent consideration liability is our only Level 3 asset or liability. A summary of the Level 3 activity follows: Contingent Consideration (in millions) Balance at October 31, 2020 $ — Additions to contingent consideration (including measurement period adjustment) 110 Change in fair value (included within selling, general and administrative expenses) (21) Balance at October 31, 2021 $ 89 Additions to contingent consideration 3 Change in fair value (included within selling, general and administrative expenses) (25) Balance at October 31, 2022 67
Impairment of Long-lived assets included in net income	For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2022, 2021 and 2020: Years Ended 2022 2021 2020 (in millions) Long-lived assets held and used $ — $ 2 $ 98 Long-lived assets held for sale $ — $ — $ —

DERIVATIVES (Tables)

DERIVATIVES (Tables)	12 Months Ended
DERIVATIVES (Tables)	Oct. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of October 31, 2022 were as follows: Derivatives Designated as Derivatives Designated as Derivatives Forward Forward Forward Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (78) $ (10) $ (18) British Pound (66) — 13 Canadian Dollar (55) — (17) Japanese Yen (93) — (42) Danish Krone — — 25 Korean Won (90) — (10) Singapore Dollar 19 — 24 Swiss Franc — — (13) Chinese Yuan Renminbi (87) — (100) Taiwan Dollar — — (16) India Rupee — — (11) Other 4 — 3 $ (446) $ (10) $ (162)
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2022 and 2021 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location October 31, October 31, Balance Sheet Location October 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 23 $ 6 Other accrued liabilities $ 2 $ 2 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 8 $ 3 Other accrued liabilities $ 3 $ 3 Total derivatives $ 31 $ 9 $ 5 $ 5
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Years Ended October 31, 2022 2021 2020 (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts: Loss reclassified from accumulated other comprehensive income (loss) into interest expense $ (2) $ (1) $ (1) Gain (loss) recognized in accumulated other comprehensive income (loss) $ 56 $ 2 $ (12) Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ 36 $ (16) $ (1) Gain on time value of forward contracts recorded in cost of sales $ — $ — $ 2 Net investment hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) - translation adjustment $ 5 $ 1 $ (5) Gain on time value of forward contracts recorded in other income (expense) — 1 — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense), net $ 10 $ — $ (1)

RETIREMENT PLANS AND POST RET_2

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	12 Months Ended
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	Oct. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Schedule of Net Benefit Costs	For the years ended October 31, 2022, 2021 and 2020, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: Pensions U.S. Post-Retirement Benefit Plans U.S. Plans Non-U.S. Plans 2022 2021 2020 2022 2021 2020 2022 2021 2020 (in millions) Net periodic benefit cost (benefit) Service cost — benefits earned during the period $ — $ — $ — $ 22 $ 22 $ 24 $ 1 $ 1 $ 1 Interest cost on benefit obligation 14 14 15 9 8 8 2 2 3 Expected return on plan assets (27) (29) (28) (43) (49) (47) (6) (6) (7) Amortization of net actuarial (gain) loss — 4 3 25 53 49 (2) 4 4 Amortization of prior service benefit — — — — — — (1) (1) (7) Total periodic benefit cost (benefit) $ (13) $ (11) $ (10) $ 13 $ 34 $ 34 $ (6) $ — $ (6) Settlement loss $ 4 $ 1 $ 4 $ — $ — $ — $ — $ — $ — Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Net actuarial (gain) loss $ 16 $ (92) $ 26 $ (83) $ (114) $ 20 $ 15 $ (30) $ 5 Amortization of net actuarial (gain) loss — (4) (3) (25) (53) (49) 2 (4) (4) Amortization of prior service benefit — — — — — — 1 1 7 Loss due to settlement (4) (1) (4) — — — — — — Foreign currency — — — 11 5 10 — — — Total recognized in other comprehensive (income) loss $ 12 $ (97) $ 19 $ (97) $ (162) $ (19) $ 18 $ (33) $ 8 Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 3 $ (107) $ 13 $ (84) $ (128) $ 15 $ 12 $ (33) $ 2
Schedule of Funded status of Defined Benefit and Post-Retirement Benefit plans	Funded Status. As of October 31, 2022 and 2021, the funded status of the defined benefit and post-retirement benefit plans was: U.S. Defined Non-U.S. Defined U.S. 2022 2021 2022 2021 2022 2021 (in millions) Change in fair value of plan assets: Fair value — beginning of year $ 551 $ 439 $ 1,093 $ 945 $ 116 $ 93 Actual return on plan assets (122) 138 (147) 160 (26) 28 Employer contributions — — 17 19 — — Participants' contributions — — 1 1 — — Benefits paid (10) (8) (35) (31) (5) (5) Settlements (23) (18) — — — — Currency impact — — (181) (1) — — Fair value — end of year $ 396 $ 551 $ 748 $ 1,093 $ 85 $ 116 Change in benefit obligation: Benefit obligation — beginning of year $ 512 $ 510 $ 1,100 $ 1,094 $ 84 $ 94 Service cost — — 22 22 1 1 Interest cost 14 14 9 8 2 2 Participants' contributions — — 1 1 — — Actuarial (gain) loss (133) 15 (262) 2 (17) (8) Benefits paid (10) (8) (35) (31) (5) (5) Settlements (26) (19) — — — — Currency impact — — (170) 4 — — Benefit obligation — end of year $ 357 $ 512 $ 665 $ 1,100 $ 65 $ 84 Overfunded (underfunded) status of PBO $ 39 $ 39 $ 83 $ (7) $ 20 $ 32
Amounts recognized in the consolidated balance sheet	Amounts recognized in the consolidated balance sheet consist of: Other assets $ 42 $ 46 $ 140 $ 160 $ 20 $ 32 Employee compensation and benefits (1) (1) — — — — Retirement and post-retirement benefits (2) (6) (57) (167) — — Total net asset (liability) $ 39 $ 39 $ 83 $ (7) $ 20 $ 32
Amounts recognized in accumulated other comprehensive income (loss)	Amounts Recognized in Accumulated Other Comprehensive Income (Loss): Actuarial (gains) losses $ 48 $ 36 $ 52 $ 149 $ (6) $ (23) Prior service costs (benefits) — — — — (3) (4) Total $ 48 $ 36 $ 52 $ 149 $ (9) $ (27)
Schedule of Allocation of Plan Assets	The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2022 and 2021. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 1 $ — $ — $ — $ 1 Equity 194 49 — — 145 Fixed Income 199 — — — 199 Other Investments 2 — — 2 — Total assets measured at fair value $ 396 $ 49 $ — $ 2 $ 345 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 2 $ — $ — $ — $ 2 Equity 276 62 — — 214 Fixed Income 271 2 — — 269 Other Investments 2 — — 2 — Total assets measured at fair value $ 551 $ 64 $ — $ 2 $ 485 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2022 and 2021. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ — $ — $ — $ — $ — Equity 42 10 — — 32 Fixed Income 42 — — — 42 Other Investments 1 — — 1 — Total assets measured at fair value $ 85 $ 10 $ — $ 1 $ 74 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 3 $ — $ — $ — $ 3 Equity 55 13 — — 42 Fixed Income 57 — — — 57 Other Investments 1 — — 1 — Total assets measured at fair value $ 116 $ 13 $ — $ 1 $ 102 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2022 and 2021: Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 22 $ — $ 22 $ — $ — Equity 360 264 — — 96 Fixed Income 274 83 98 — 93 Annuity Contract 92 — — 92 — Total assets measured at fair value $ 748 $ 347 $ 120 $ 92 $ 189 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement October 31, Quoted Prices Significant Significant Not Subject to Leveling (1)(2) (in millions) Cash and Cash Equivalents $ 25 $ — $ 24 $ — $ 1 Equity 543 380 12 — 151 Fixed Income 525 151 242 — 132 Total assets measured at fair value $ 1,093 $ 531 $ 278 $ — $ 284 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. (2) Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications have no effect on the previously reported financial statements and other notes to the financial statements.
Defined benefit plans assets measured at fair value using significant unobservable inputs (level 3)	For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2022 and 2021: Years Ended 2022 2021 Balance, beginning of year $ 2 $ 2 Realized gains/(losses) — 1 Unrealized gains/(losses) — — Purchases, sales, issuances, and settlements — (1) Transfers in (out) — — Balance, end of year $ 2 $ 2 For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2022 and 2021: Years Ended 2022 2021 Balance, beginning of year $ 1 $ 1 Realized gains/(losses) — 1 Unrealized gains/(losses) — — Purchases, sales, issuances, and settlements — (1) Transfers in (out) — — Balance, end of year $ 1 $ 1 For non-U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2022 and 2021: Years Ended 2022 2021 Balance, beginning of year $ — $ — Realized gains/(losses) — — Unrealized gains/(losses) (39) — Purchases, sales, issuances, and settlements (5) — Transfers in (out) 159 — Currency impact (23) — Balance, end of year $ 92 $ —
Combined projected benefit obligation, accumulated benefit obligations and fair value of plan assets	The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2022 or 2021. 2022 2021 Benefit Benefit Fair Value of Fair Value of PBO PBO (in millions) U.S. defined benefit plans where PBO exceeds the fair value of plan assets $ 3 $ — $ 7 $ — U.S. defined benefit plans where fair value of plan assets exceeds PBO 354 396 505 551 Total $ 357 $ 396 $ 512 $ 551 Non-U.S. defined benefit plans where PBO exceeds the fair value of plan assets $ 172 $ 114 $ 691 $ 524 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 493 634 409 569 Total $ 665 $ 748 $ 1,100 $ 1,093 ABO ABO U.S. defined benefit plans where ABO exceeds the fair value of plan assets $ 3 $ — $ 7 $ — U.S. defined benefit plans where the fair value of plan assets exceeds ABO 354 396 505 551 Total $ 357 $ 396 $ 512 $ 551 Non-U.S. defined benefit plans where ABO exceeds the fair value of plan assets $ 167 $ 114 $ 668 $ 524 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO 485 634 400 569 Total $ 652 $ 748 $ 1,068 $ 1,093
Schedule of expected benefit payments	The following table presents expected future benefit payments for the next 10 years: U.S. Defined Non-U.S. Defined U.S. Post-Retirement (in millions) 2023 $ 31 $ 32 $ 6 2024 $ 34 $ 33 $ 6 2025 $ 32 $ 34 $ 7 2026 $ 32 $ 34 $ 7 2027 $ 32 $ 35 $ 7 2028 - 2032 $ 142 $ 187 $ 34
Assumptions used to calculate the net periodic cost and benefit obligation	Assumptions used to calculate the net periodic cost (benefit) in each year were as follows: For years ended October 31, 2022 2021 2020 U.S. defined benefit plans: Discount rate 2.75% 2.75% 3.25% Expected long-term return on assets 5.00% 7.00% 7.00% Non-U.S. defined benefit plans: Discount rate 0.29-1.76% 0.07-1.54% 0.22-1.81% Average increase in compensation levels 2.00-3.50% 2.00-3.00% 2.25-3.00% Expected long-term return on assets 2.75-5.50% 4.00-5.50% 4.00-5.75% Interest crediting rate for cash balance plans 0.30-0.50% 0.10-0.50% 0.00-0.75% U.S. post-retirement benefits plans: Discount rate 2.75% 2.50% 3.00% Expected long-term return on assets 5.00% 7.00% 7.00% Current medical cost trend rate 6.00% 6.25% 6.25% Ultimate medical cost trend rate 4.50% 4.50% 4.50% Medical cost trend rate decreases to ultimate rate in year 2027 2029 2029 Assumptions used to calculate the benefit obligation were as follows: As of the Years Ending October 31, 2022 2021 U.S. defined benefit plans: Discount rate 6.00% 2.75% Non-U.S. defined benefit plans: Discount rate 1.50-4.77% 0.29-1.76% Average increase in compensation levels 2.00-3.25% 2.00-3.50% Interest crediting rate for cash balance plans 0.50-2.10% 0.30-0.50% U.S. post-retirement benefits plans: Discount rate 6.00% 2.75% Current medical cost trend rate 7.00% 6.00% Ultimate medical cost trend rate 4.75% 4.50% Medical cost trend rate decreases to ultimate rate in year 2029 2027

GUARANTEES (Tables)

GUARANTEES (Tables)	12 Months Ended
GUARANTEES (Tables)	Oct. 31, 2022
Guarantees [Abstract]
Standard Warranty	A summary of the standard warranty accrual activity is shown in the table below. October 31, 2022 2021 (in millions) Standard warranty accrual, beginning balance $ 30 $ 32 Accruals for warranties including change in estimates 50 52 Settlements made during the period (50) (54) Standard warranty accrual, ending balance $ 30 $ 30
Schedule of Product Warranty Liability classification	Accruals for warranties due within one year $ 30 $ 29 Accruals for warranties due after one year — 1 Standard warranty accrual, ending balance $ 30 $ 30

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
LONG-TERM DEBT (Tables)	Oct. 31, 2022
Debt Disclosure [Abstract]
Long-term debt - Senior Notes	The following table summarizes the company's long-term senior notes: October 31, 2022 October 31, 2021 Amortized Amortized (in millions) 2023 Senior Notes $ — $ 599 2026 Senior Notes 299 298 2029 Senior Notes 495 494 2030 Senior Notes 496 496 2031 Senior Notes 843 842 Total Senior Notes $ 2,133 $ 2,729

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Oct. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2022 and 2021, net of tax effect: October 31, 2022 2021 (in millions) Foreign currency translation, net of tax (expense) benefit of $4 and $(8) $ (335) (185) Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $71 and $80 (32) (100) Unrealized gains (losses) on derivative instruments, net of tax (expense) benefit of $(4) and $1 20 3 Total accumulated other comprehensive loss $ (347) $ (282) Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2022 and 2021 were as follows: Net defined benefit pension cost and post retirement plan costs Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2020 $ (194) $ 125 $ (442) $ (11) $ (522) Other comprehensive income before reclassifications 11 — 228 2 241 Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 64 17 80 Tax expense (2) — (74) (5) (81) Other comprehensive income (loss) 9 (1) 218 14 240 As of October 31, 2021 $ (185) $ 124 $ (224) $ 3 $ (282) Other comprehensive income (loss) before reclassifications (162) — 50 56 (56) Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 28 (34) (7) Tax (expense) benefit 12 — (9) (5) (2) Other comprehensive income (loss) (150) (1) 69 17 (65) As of October 31, 2022 $ (335) $ 123 $ (155) $ 20 $ (347)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2022 and 2021 were as follows (in millions): Details about Accumulated Other Amounts Reclassified Affected line item in 2022 2021 Unrealized gains (losses) on derivatives $ 36 $ (16) Cost of products Unrealized gains (losses) on derivatives (2) (1) Interest expense 34 (17) Total before income tax (8) 4 (Provision) benefit for income tax 26 (13) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (28) (64) Other (income) expense Prior service benefit 1 1 Other (income) expense (27) (63) Total before income tax 7 15 Benefit for income tax (20) (48) Total net of income tax Total reclassifications for the period $ 6 $ (61)

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
SEGMENT INFORMATION (Tables)	Oct. 31, 2022
Revenue from External Customer [Line Items]
Segment profitability	The profitability of each of the segments is measured after excluding items such as asset impairment charges, transformational initiatives, acquisition and integration costs, non-cash amortization of intangible assets related to business combinations, interest income, interest expense, and other items as noted in the reconciliations below. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Year Ended October 31, 2022: Total net revenue $ 4,007 $ 1,389 $ 1,452 $ 6,848 Income from operations $ 1,186 $ 301 $ 370 $ 1,857 Depreciation expense $ 59 $ 39 $ 22 $ 120 Share-based compensation expense (1) $ 69 $ 25 $ 26 $ 120 Year Ended October 31, 2021: Total net revenue $ 3,663 $ 1,296 $ 1,360 $ 6,319 Income from operations $ 1,017 $ 273 $ 323 $ 1,613 Depreciation expense $ 60 $ 39 $ 23 $ 122 Share-based compensation expense (1) $ 60 $ 22 $ 24 $ 106 Year Ended October 31, 2020: Total net revenue $ 3,115 $ 1,047 $ 1,177 $ 5,339 Income from operations $ 792 $ 192 $ 272 $ 1,256 Depreciation expense $ 58 $ 39 $ 22 $ 119 Share-based compensation expense (1) $ 46 $ 17 $ 18 $ 81 (1) Share-based compensation expense in 2022, 2021 and 2020 excludes amounts not allocated to the segments related to accelerated share-based compensation expense from workforce reduction and from our acquisition of BioTek and Resolution Bioscience.
Reconciliation of segment results to total enterprise results	The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes: Years Ended October 31, 2022 2021 2020 (in millions) Total reportable segments' income from operations $ 1,857 $ 1,613 $ 1,256 Amortization of intangible assets related to business combinations (191) (194) (184) Acquisition and integration costs (25) (41) (41) Transformational initiatives (30) (37) (53) Acceleration of share-based compensation expense related to workforce reduction — (1) (2) Asset impairments — (2) (99) Business exit and divestiture costs (7) (5) (2) Change in fair value of contingent consideration 25 21 — Special compliance costs — (1) — Other (1) (11) (6) (29) Interest Income 9 2 8 Interest Expense (84) (81) (78) Other income (expense), net (2) (39) 92 66 Income before taxes, as reported $ 1,504 $ 1,360 $ 842 (1) For the year ended October 31, 2020, the other category primarily includes legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments. (2) For the year ended October 31, 2022 and 2021, other income (expense), net includes net gains and losses on the fair value of equity securities. For the year ended October 31, 2020, other income (expense), net includes the settlement of a legal claim against Twist Bioscience Corporation.
Assets and capital expenditures directly managed by each segment	The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of use assets and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) As of and for the Year Ended October 31, 2022: Assets $ 3,955 $ 3,489 $ 869 $ 8,313 Capital expenditures $ 77 $ 181 $ 33 $ 291 As of and for the Year Ended October 31, 2021: Assets $ 3,741 $ 3,320 $ 839 $ 7,900 Capital expenditures $ 64 $ 100 $ 24 $ 188 The following table reconciles segment assets to Agilent's total assets: October 31, 2022 2021 (in millions) Total reportable segments' assets $ 8,313 $ 7,900 Cash and cash equivalents 1,053 1,484 Short-term investments — 91 Prepaid expenses 119 91 Long-term investments 195 185 Long-term and other receivables 134 126 Deferred tax assets 246 309 Right of use assets 150 178 Other 322 341 Total assets $ 10,532 $ 10,705 The other category primarily includes over funded pension plans which are not allocated to the segments.
Revenue and assets by geographic areas	The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location. United China (1) Rest of the Total (in millions) Net revenue: Year Ended October 31, 2022 $ 2,385 $ 1,499 $ 2,964 $ 6,848 Year Ended October 31, 2021 $ 2,159 $ 1,273 $ 2,887 $ 6,319 Year Ended October 31, 2020 $ 1,752 $ 1,087 $ 2,500 $ 5,339 1. China also includes Hong Kong net revenue. The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe. United Germany Rest of the Total (in millions) Long-lived assets: October 31, 2022 $ 1,080 $ 151 $ 492 $ 1,723 October 31, 2021 $ 912 $ 134 $ 587 $ 1,633

OVERVIEW AND SUMMARY OF SIGNI_4

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions		12 Months Ended
	Nov. 01, 2022	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Advertising Expense
Advertising costs expensed as incurred		$ 66	$ 63	$ 48
Cash and Cash Equivalents
Short-term Investments		0	91
Cash and cash equivalents		1,053	1,484	1,441
Restricted Cash		3	6	6
Cash, cash equivalents and restricted cash		1,056	1,490	1,447	$ 1,388
Goodwill and Intangible Assets
Goodwill impairment	$ 0	0	0	0
Impairment of indefinite-lived intangible assets		0	0	90
Long -Lived Assets
Impairment of Long-Lived Assets		0	2	98
Variable Interest Entity
Assets		10,532	10,705
Fair Value Disclosures
Equity Method Investments		0	0
Carrying Value of Senior Notes		2,733	2,729
Employee Compensation and Benefits
Employee compensation and benefits accrued		123	129
Share-based Payment Arrangement, Noncash Expense [Abstract]
Share-based compensation expense		126	111	84
Foreign Currency Translation
Foreign currency translation net gain (Ioss)		$ (6)	$ (4)	$ (4)
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]				Research and Development Expense
Accounts Receivable
Accounts Receivable
Percent of Accounts receivable from a single customer		No single customer accounted for more than 10 percent of accounts receivable	No single customer accounted for more than 10 percent of accounts receivable
Senior Notes
Fair Value Disclosures
Carrying Value of Senior Notes		$ 2,133	$ 2,729
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Senior Notes
Fair Value Disclosures
Fair Value of Senior Notes		1,754	2,806
Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity
Assets		87	$ 76
Non-US
Cash and Cash Equivalents
Cash and cash equivalents		$ 1,028
Minimum
Goodwill and Intangible Assets
Finite Lived Intangible Assets Useful Life		6 months
Minimum \| Machinery and Equipment
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Useful Life		3 years
Minimum \| Software Development
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Useful Life		3 years
Maximum
Goodwill and Intangible Assets
Finite Lived Intangible Assets Useful Life		15 years
Maximum \| Machinery and Equipment
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Useful Life		10 years
Maximum \| Software Development
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Useful Life		5 years

REVENUE - Revenue by Region (De

REVENUE - Revenue by Region (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 6,848	$ 6,319	$ 5,339
Americas
Disaggregation of Revenue [Line Items]
Net revenue	2,682	2,404	1,968
Europe
Disaggregation of Revenue [Line Items]
Net revenue	1,699	1,688	1,443
Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	2,467	2,227	1,928
Life Sciences and Applied Markets
Disaggregation of Revenue [Line Items]
Net revenue	4,007	3,663	3,115
Life Sciences and Applied Markets \| Americas
Disaggregation of Revenue [Line Items]
Net revenue	1,331	1,199	1,002
Life Sciences and Applied Markets \| Europe
Disaggregation of Revenue [Line Items]
Net revenue	907	893	746
Life Sciences and Applied Markets \| Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	1,769	1,571	1,367
Diagnostics and Genomics
Disaggregation of Revenue [Line Items]
Net revenue	1,389	1,296	1,047
Diagnostics and Genomics \| Americas
Disaggregation of Revenue [Line Items]
Net revenue	784	695	517
Diagnostics and Genomics \| Europe
Disaggregation of Revenue [Line Items]
Net revenue	410	417	371
Diagnostics and Genomics \| Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	195	184	159
Agilent CrossLab
Disaggregation of Revenue [Line Items]
Net revenue	1,452	1,360	1,177
Agilent CrossLab \| Americas
Disaggregation of Revenue [Line Items]
Net revenue	567	510	449
Agilent CrossLab \| Europe
Disaggregation of Revenue [Line Items]
Net revenue	382	378	326
Agilent CrossLab \| Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	$ 503	$ 472	$ 402

REVENUE - Revenue by End Market

REVENUE - Revenue by End Markets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 6,848	$ 6,319	$ 5,339
Pharmaceutical and Biopharmaceutical Market
Disaggregation of Revenue [Line Items]
Net revenue	2,515	2,224	1,754
Chemical and Energy Market
Disaggregation of Revenue [Line Items]
Net revenue	1,521	1,328	1,154
Diagnostics and Clinical Market
Disaggregation of Revenue [Line Items]
Net revenue	963	938	787
Food Market
Disaggregation of Revenue [Line Items]
Net revenue	617	601	517
Academia and Government Market
Disaggregation of Revenue [Line Items]
Net revenue	576	576	526
Environmental and Forensics Market
Disaggregation of Revenue [Line Items]
Net revenue	$ 656	$ 652	$ 601

REVENUE - Revenue by Type (Deta

REVENUE - Revenue by Type (Details) - USD ($) $ in Millions	12 Months Ended
REVENUE - Revenue by Type (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 6,848	$ 6,319	$ 5,339
Instrumentation
Disaggregation of Revenue [Line Items]
Net revenue	2,907	2,657	2,249
Non-Instrumentation and Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 3,941	$ 3,662	$ 3,090

REVENUE - Contract Balances (De

REVENUE - Contract Balances (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Contract Assets	$ 275	$ 197
Contract Liability ending balance	519	446
Net revenue deferred in the period	437	406
Revenue recognized that was included in the contract liability balance at the beginning of the period	(372)	(359)
Change in deferrals from customer cash advances, net of revenue recognized	11	24
Currency translation and other adjustments	(38)	2
Contract Liability ending balance	557	$ 519
Revenue, Remaining Performance Obligation, Amount	$ 357
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

SHARE-BASED COMPENSATION Genera

SHARE-BASED COMPENSATION General Disclosures (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Employee stock purchase plan [Abstract]
Compensation percentage maximum eligible contribution to purchase shares of common stock	10%
Maximum number of shares authorized for issuance under the ESPP (in shares)	31,000,000
Number of shares purchased under ESPP (in shares)	469,701	462,237	628,644
Aggregate Value stock issued under Employee Stock Purchase Plan	$ 54	$ 46	$ 41
Aggregate participants contributions to ESPP	$ 27
Incentive compensation plans [Abstract]
Common stock available for future awards under the 2018 Stock Plan (in shares)	21,496,468
Employee Stock Purchase Plan
Employee stock purchase plan [Abstract]
Percent of market price	85%
Incentive compensation plans [Abstract]
Common stock available for future awards under the 2018 Stock Plan (in shares)	24,859,446
Share-based Payment Arrangement, Option
Employee stock purchase plan [Abstract]
Percent of market price	100%
Incentive compensation plans [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Percentage which rate options generally vest per year (in hundredths)	25%
Number of years from the date of grant generally vest (in years)	4 years
Restricted Stock Units (RSUs)
Incentive compensation plans [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Percentage which rate options generally vest per year (in hundredths)	25%
Number of years from the date of grant generally vest (in years)	4 years
Long-Term Performance Plan
Incentive compensation plans [Abstract]
Number of years from the date of grant generally vest (in years)	3 years
Long-Term Performance Plan \| Minimum
Incentive compensation plans [Abstract]
Percentage which rate options generally vest per year (in hundredths)	0%
Long-Term Performance Plan \| Maximum
Incentive compensation plans [Abstract]
Percentage which rate options generally vest per year (in hundredths)	200%

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Share-based compensation disclosures
Share-based compensation expense	$ 126	$ 111	$ 84
Cost of Product and Services
Share-based compensation disclosures
Share-based compensation expense	30	26	21
Research and Development
Share-based compensation disclosures
Share-based compensation expense	14	12	9
Selling, General and Administrative
Share-based compensation disclosures
Share-based compensation expense	82	73	$ 54
Inventories
Share-based Payment Arrangement, Expensed and Capitalized, Amount
Share-based compensation expense	$ 0	$ 0

SHARE-BASED COMPENSATION-Fair V

SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)	12 Months Ended
SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate	1.50%	0.50%
Dividend Yield	0.50%	0.70%
Weighted Average Volatility	26%	26%
Expected life	5 years 6 months	5 years 6 months
Percent of market price	100%
Long-Term Performance Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility of Agilent shares (in hundreths)	29%	30%	23%
Volatility of peer-company shares -Minimum	23%	24%	15%
Volatility of peer-company shares -Maximum	81%	57%	44%
Pair-wise correlation with selected peers (in hundredths)	41%	45%	29%
LTPP & RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-vest restriction discount for all executive awards	6.50%	6.80%	5.30%

SHARE-BASED COMPENSATION Stock

SHARE-BASED COMPENSATION Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance (in shares)	943
Granted (in shares)	279
Exercised (in shares)	(108)
Cancelled (in shares)	(17)
Outstanding, ending balance (in shares)	1,097	943
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, Weighted Average option Exercise Price	$ 94	$ 69
Options, Grants in Period, Weighted Average Exercise Price	158
Weighted-average exercise price per share, exercised (in dollars per share)	38	$ 33	$ 34
Weighted-average exercise price per share, cancelled, expired and forfeited (in dollars per shares)	$ 130
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 10,765	$ 34,305	$ 30,481
Black Scholes per share value of options granted during fiscal year	$ 39	$ 26

SHARE-BASED COMPENSATION Shares

SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Number Outstanding (in shares)	1,097
Weighted Average Remaining Contractual Life (in years)	5 years 9 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 94
Aggregate Intrinsic Value - Options outstanding	$ 54,455,000
Number Exercisable (in shares)	560
Weighted Average Remaining Contractual Life (in years)	3 years 1 month 6 days
Weighted Average Exercise Price (in dollars per share)	$ 54
Aggregate Intrinsic Value - Options Exercisable	$ 47,168,000
Incentive compensation plans [Abstract]
In-the-money awards exercisable (in shares)	600
Aggregate instrinsic value of options [Abstract]
Amount of cash received from the exercise of share-based awards granted	$ 58,000,000	$ 55,000,000	$ 60,000,000
Share Price	$ 138.35
Range of Exercise Prices - $25.00 - $40.00
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding in the period (in dollars per share)	25
Maximum price of options outstanding, end of the period (in dollars per share)	$ 40
Number Outstanding (in shares)	69
Weighted Average Remaining Contractual Life (in years)	1 year
Weighted Average Exercise Price (in dollars per share)	$ 38
Aggregate Intrinsic Value - Options outstanding	$ 6,958,000
Number Exercisable (in shares)	69
Weighted Average Remaining Contractual Life (in years)	1 year
Weighted Average Exercise Price (in dollars per share)	$ 38
Aggregate Intrinsic Value - Options Exercisable	$ 6,958,000
Range of Exercise Prices - $40.01 - $50.00
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding in the period (in dollars per share)	$ 40.01
Maximum price of options outstanding, end of the period (in dollars per share)	$ 50
Number Outstanding (in shares)	386
Weighted Average Remaining Contractual Life (in years)	2 years
Weighted Average Exercise Price (in dollars per share)	$ 41
Aggregate Intrinsic Value - Options outstanding	$ 37,556,000
Number Exercisable (in shares)	386
Weighted Average Remaining Contractual Life (in years)	2 years
Weighted Average Exercise Price (in dollars per share)	$ 41
Aggregate Intrinsic Value - Options Exercisable	$ 37,556,000
Range of Exercise Prices $100.00 - $110.00
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding in the period (in dollars per share)	$ 100
Maximum price of options outstanding, end of the period (in dollars per share)	$ 110
Number Outstanding (in shares)	325
Weighted Average Remaining Contractual Life (in years)	8 years
Weighted Average Exercise Price (in dollars per share)	$ 110
Aggregate Intrinsic Value - Options outstanding	$ 9,254,000
Number Exercisable (in shares)	90
Weighted Average Remaining Contractual Life (in years)	8 years
Weighted Average Exercise Price (in dollars per share)	$ 110
Aggregate Intrinsic Value - Options Exercisable	$ 2,555,000
Range of Exercise Prices - $110.01 - $150.00
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding in the period (in dollars per share)	$ 110.01
Maximum price of options outstanding, end of the period (in dollars per share)	$ 150,000
Number Outstanding (in shares)	65
Weighted Average Remaining Contractual Life (in years)	8 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 128
Aggregate Intrinsic Value - Options outstanding	$ 687,000
Number Exercisable (in shares)	9
Weighted Average Remaining Contractual Life (in years)	8 years 6 months
Weighted Average Exercise Price (in dollars per share)	$ 127
Aggregate Intrinsic Value - Options Exercisable	$ 99,000
Range of Exercise Prices - $150.01 & over
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding in the period (in dollars per share)	$ 150.01
Number Outstanding (in shares)	252
Weighted Average Remaining Contractual Life (in years)	9 years
Weighted Average Exercise Price (in dollars per share)	$ 161
Aggregate Intrinsic Value - Options outstanding	$ 0
Number Exercisable (in shares)	6
Weighted Average Remaining Contractual Life (in years)	9 years
Weighted Average Exercise Price (in dollars per share)	$ 159
Aggregate Intrinsic Value - Options Exercisable	$ 0
Share-based Payment Arrangement, Option
Aggregate instrinsic value of options [Abstract]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 8,000,000

SHARE-BASED COMPENSATION Non-ve

SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Oct. 31, 2022 USD ($) yr $ / shares shares	Oct. 31, 2021 USD ($) shares	Oct. 31, 2020 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested beginning (in shares) \| shares	2,519
Granted (in shares) \| shares	696
Vested (in shares) \| shares	(1,189)
Forfeited (in shares) \| shares	(112)
Change in LTPP shares vested in the year due to performance conditions \| shares	189
Non-vested ending (in shares) \| shares	2,103	2,519
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Non-vested at October 31, 2021 -Weighted Average Grant Price (in dollars per share) \| $ / shares	$ 88
Granted - Weighted Average Grant Price (in dollars per share) \| $ / shares	155
Vested- Weighted Average Grant Price (in dollars per share) \| $ / shares	75
Foreited- Weighted Average Grant Price (in dollars per share) \| $ / shares	114
Change in LTPP shares vested in the year- Weighted Average Grant Date Fair Value \| $ / shares	65
Non-vested at October 31, 2020 -Weighted Average Grant Price (in dollars per share) \| $ / shares	$ 114
Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures \| $	$ 115
Weighted-average period non-vested restricted stock awards are expected to be amortized over (in years) \| yr	2.1
Total fair value of restricted stock awards vested \| $	$ 89	$ 84	$ 85

INCOME TAXES INCOME TAXES- Prov

INCOME TAXES INCOME TAXES- Provision (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Income before income tax
U.S. operations	$ 858	$ 876	$ 54
Non-U.S. operations	646	484	788
Income before taxes	1,504	1,360	842
Provision (benefit) for income taxes
U.S. federal taxes - current	173	122	5
U.S. federal taxes - deferred	(28)	(1)	4
Non-U.S. taxes - current	47	(3)	84
Non-U.S. taxes - deferred	35	14	24
State taxes, net of federal benefit - current	22	17	5
State taxes, net of federal benefit - deferred	1	1	1
Provision for income taxes	$ 250	$ 150	$ 123

INCOME TAXES Effective tax rate

INCOME TAXES Effective tax rate (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Profit before tax times statutory rate	$ 316	$ 286	$ 177
State income taxes, net of federal benefit	23	18	6
Non-U.S. income taxed at different rates	(18)	5	(37)
Change in unrecognized tax benefits)	(6)	(84)	(8)
Effective Income Tax Rate Reconciliation, FDII, Amount	(46)	(35)	(9)
Excess tax benefits from stock-based compensation	(19)	(29)	(18)
Other, net	0	(11)	12
Provision for income taxes	$ 250	$ 150	$ 123
Effective tax rate (in hundredths)	16.60%	11%	14.60%
Effective Income Tax Rate Reconciliation, Tax Settlement, Amount		$ 93

INCOME TAXES INCOME TAXES Tax h

INCOME TAXES INCOME TAXES Tax holidays (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Income Tax Holiday [Line Items]
Impact of the income tax holidays	$ 53	$ 35	$ 71
Benefit of income tax holidays on net income per share	$ 0.18	$ 0.11	$ 0.23

INCOME TAXES INCOME TAXES - Def

INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Components of Deferred Tax Assets
Intangibles	$ 62	$ 72
Employee benefits, other than retirement	45	43
Net operating loss, capital loss and credit carryforwards	157	191
Share-based compensation	23	22
Lease obligations	29	30
Other	58	42
Subtotal	374	400
Tax valuation allowance	(115)	(120)
Deferred tax assets	259	280
Components of Deferred Tax Liabilities
Property, plant and equipment	(11)	(11)
Pension benefits and retiree medical benefits	(24)	(8)
Right-of-use asset	(29)	(29)
Other	(7)	(26)
Deferred tax liability	(71)	(74)
Deferred Tax Assets, Net	188	206
Long Term Deferred Tax Assets And Liabilities [Abstract]
Long-term deferred tax assets ( included within other assets)	259	280
Deferred Tax Assets, Net	188	206
Other Noncurrent Assets [Member]
Components of Deferred Tax Assets
Deferred tax assets	246	309
Long Term Deferred Tax Assets And Liabilities [Abstract]
Long-term deferred tax assets ( included within other assets)	246	309
Other Noncurrent Liabilities
Long Term Deferred Tax Assets And Liabilities [Abstract]
Long-term deferred tax liabilities ( included within other long-term liabilities)	$ 58	$ 103

INCOME TAXES - Carryforwards (D

INCOME TAXES - Carryforwards (Details) $ in Millions	Oct. 31, 2022 USD ($)
Net Operating loss carryforwards
Federal net operating loss carryforwards	$ 6
State net operating loss carryforwards	207
Foreign net operating loss carryforwards	384
Foreign
Net Operating loss carryforwards
Net operating loss carryforwards, subject to expiration	3
Net operating loss carryforwards, not subject to expiration	381
Domestic
Capital Loss Carryforward
Capital loss carryforwards	108
State
Tax Credit Carryforwards
Tax credit carryforwards	$ 87

INCOME TAXES - Current and long

INCOME TAXES - Current and long-term income tax assets and liabilities (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Income Tax Disclosure [Abstract]
Current income tax assets (included within other current assets)	$ 87	$ 66
Long-term income tax assets (included within other assets)	11	6
Current income tax liabilities (included within other accrued liabilities)	(51)	(47)
Long-term income tax liabilities (included within other long-term liabilities)	(216)	(241)
Total	$ 169	$ 216

INCOME TAXES INCOME TAXES - Unc

INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Unrecognized Tax Benefits Rollforward
Balance, beginning of year	$ 133	$ 195	$ 206
Additions for tax positions related to the current year	5	6	6
Additions for tax positions from prior years	0	4	0
Reductions for tax positions from prior years	9	0	0
Settlements with taxing authorities	0	(30)	0
Statute of limitations expirations	6	42	17
Balance, end of year	123	133	195
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	121
Interest and penalties accrued related to unrecognized tax benefits accrued and reported	21	26
Unrecognized Tax Benefits, including interest and penalties	144
Provision (benefit) for income taxes	250	150	123
State and Local Jurisdiction
Unrecognized Tax Benefits Rollforward
Balance, end of year	23
Tax Interest and Penalties
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense			$ 8
Provision (benefit) for income taxes	$ (2)	$ (19)

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Numerator:
Net Income	$ 1,254	$ 1,210	$ 719
Denominator:
Basic weighted average shares	299	304	309
Potential common shares - stock options and other employeee stock plans	1	3	3
Diluted weighted average shares	300	307	312
Share-based awards issued
Total number of share-based awards issued (in shares)	1.4	2.1	2.4

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	12 Months Ended
INVENTORY (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Inventory [Line Items]
Finished goods	$ 555	$ 463
Purchased parts and fabricated assemblies	483	367
Inventory	1,038	830
Inventory-related excess and obsolescence charges	$ 24	$ 29	$ 28

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Property, Plant and Equipment [Line Items]
Land	$ 59	$ 61
Buildings and leasehold improvements	1,255	1,147
Machinery and equipment	674	638
Software	260	221
Total property, plant and equipment	2,248	2,067
Accumulated depreciation and amortization	(1,148)	(1,122)
Property, plant and equipment, net	1,100	945
Asset impairment charges	0	2	$ 6
Depreciation expense	120	122	$ 119
Fully depreciated assets no longer in use retired	$ 48	$ 35

LEASES - Lease Costs (Details)

LEASES - Lease Costs (Details) - USD ($) $ in Millions	12 Months Ended
LEASES - Lease Costs (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Leases [Abstract]
Operating Lease, Cost	$ 59	$ 59	$ 60
Short-term Lease, Cost	2	2	1
Variable Lease, Cost	15	14	14
Sublease Income	(14)	(13)	(14)
Total Lease, Cost	$ 62	$ 62	$ 61

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Leases [Abstract]
Operating cash flow from operating leases	$ 53	$ 57	$ 59
Non-cash right of use assets obtained in exchange for operating lease obligations	$ 38	$ 53	$ 37

LEASES - Supplemental Balance S

LEASES - Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Lessee, Lease, Description [Line Items]
Right-of-use asset	$ 150	$ 178
Operating lease liabilities - Current	51	52
Operating lease liabilities - Long-term	$ 101	$ 130
Operating Lease, Weighted Average Remaining Lease Term	7 years 4 months 24 days	7 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	2.40%	1.90%
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Future Minimum Lease Payment Due
2023	$ 53
2024	36
2025	20
2026	11
2027	7
Thereafter	40
Total undiscounted future minimum lease payments	167
Less: amount of lease payments representing interest	$ (15)
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current, Other Liabilities, Noncurrent
Present value of future minimum lease payments	$ 152
Less: Current liabilities	(51)	$ (52)
Long-term lease liabilities	$ 101	$ 130

LEASES - Textual (Details)

LEASES - Textual (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Leases [Abstract]
Lessor Asset under Operating Lease, original cost	$ 29	$ 38
Lessor Asset under Operating Lease, Net book Value	4	7
Sales-type Lease, Lease Receivable	$ 38	$ 48

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Goodwill - Rollforward
Beginning Balance	$ 3,975	$ 3,602
Foreign currency translation impact	(42)	8
Goodwill arising from acquisitions	19	365
Ending Balance	3,952	3,975
Life Sciences and Applied Markets
Goodwill - Rollforward
Beginning Balance	1,743	1,738
Foreign currency translation impact	(19)	5
Goodwill arising from acquisitions	19	0
Ending Balance	1,743	1,743
Diagnostics and Genomics
Goodwill - Rollforward
Beginning Balance	1,964	1,599
Foreign currency translation impact	(11)	0
Goodwill arising from acquisitions	0	365
Ending Balance	1,953	1,964
Agilent CrossLab
Goodwill - Rollforward
Beginning Balance	268	265
Foreign currency translation impact	(12)	3
Goodwill arising from acquisitions	0	0
Ending Balance	$ 256	$ 268

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	$ 2,149	$ 2,314
Accumulated Amortization	1,338	1,344
Other intangible assets, net	821	981
Total amortizable intangible assets	811	970
Gross Book Value	2,159	2,325
In-Process R&D	10	11
Purchased technology
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	1,733	1,742
Accumulated Amortization	1,068	972
Other intangible assets, net	665	770
Backlog
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	8	8
Accumulated Amortization	8	3
Other intangible assets, net	0	5
Trademark/Tradename
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	196	196
Accumulated Amortization	148	133
Other intangible assets, net	48	63
Customer Relationships
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	180	357
Accumulated Amortization	105	228
Other intangible assets, net	75	129
Third-Party Technology and Licenses [Member]
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	32	11
Accumulated Amortization	9	8
Other intangible assets, net	$ 23	$ 3

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details) - USD ($) $ in Millions		12 Months Ended
	Nov. 01, 2022	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Intangible Assets, Including Goodwill)
Goodwill Additions		$ 19	$ 365
Additions and adjustments to other intangibles		35
Foreign exchange translation impact to other intangible assets		(3)	2
Goodwill and Intangible Asset Impairment [Abstract]
Goodwill impairment	$ 0	0	0	$ 0
Impairment of finite-lived intangible assets		0	0	0
Impairment of indefinite-lived intangible assets		0	0	$ 90
Business Acquisition
Write-off of fully amortized intangible assets		184
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]				Research and Development Expense
Diagnostics and Genomics
Intangible Assets, Including Goodwill)
Goodwill Additions		0	365
Life Sciences and Applied Markets
Intangible Assets, Including Goodwill)
Goodwill Additions		19	0
Business Acquisition
Goodwill, Transfers		307
Agilent CrossLab
Intangible Assets, Including Goodwill)
Goodwill Additions		0	0
Business Acquisition
Goodwill, Transfers		10
Resolution Bioscience, Inc.
Intangible Assets, Including Goodwill)
Goodwill Additions			365
Additions and adjustments to other intangibles			343
Business Acquisition
Purchase price for acquisition			$ 561
Polymer Standards Service GmbH
Business Acquisition
Purchase price for acquisition		$ 41

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Future Amortization Expense Schedule
2023	$ 145
2024	126
2025	102
2026	72
2027	71
Thereafter	295
Amortization Expense
Amortization of intangible assets during the period	$ 192	$ 195	$ 186

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($) $ in Millions	12 Months Ended
INVESTMENTS (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Long-Term [Abstract]
Equity investments - with readily determinable fair value	$ 0	$ 91
Equity investments - without readily determinable fair value	141	120
Equity investments - with readily determinable fair value	23	31
Trading securities	31	34
Long-term investments	195	185
Amounts included in other income (expense), net [Abstract]
Net (gain) loss on equity securities	(67)	98	$ 27
Net gain on equity securities sold during the period	11	6	0
Net unrealized gains on our equity securities with RDFV	(78)	92	27
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	6	17	27
Trading, Unrealized Gain (Loss)	(7)	8	2
Other than Temporary Impairment Losses, Investments	$ 0	$ 0	$ 0

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Assets, Short-term [Abstract]
Short-term Investments	$ 0	$ 91
Assets, Long-term [Abstract]
Trading securities	31	34
Total assets measured at fair value		0	$ 0
Liabilities, Long-term [Abstract]
Contingent Consideration	67	89	$ 0
Fair Value, Recurring
Assets, Long-term [Abstract]
Total assets measured at fair value	577	1,084
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	$ 5	$ 5
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Liabilities, Long-term [Abstract]
Total liabilities measured at fair value	$ 103	$ 128
Fair Value, Recurring \| Other Current Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	66	62
Fair Value, Recurring \| Other Noncurrent Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	1	27
Deferred compensation liability	31	34
Fair Value, Recurring \| Other Current Assets [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	492	919
Derivative instruments (foreign exchange contracts)	31	9
Short-term Investments		91
Fair Value, Recurring \| Other Noncurrent Assets [Member]
Assets, Long-term [Abstract]
Trading securities	31	34
Other investments	23	31
Fair Value, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets, Long-term [Abstract]
Total assets measured at fair value	523	1,036
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	$ 0	$ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Liabilities, Long-term [Abstract]
Total liabilities measured at fair value	$ 0	$ 0
Fair Value, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other Current Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	0	0
Fair Value, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other Noncurrent Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	0	0
Deferred compensation liability	0	0
Fair Value, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other Current Assets [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	492	919
Derivative instruments (foreign exchange contracts)	0	0
Short-term Investments		83
Fair Value, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other Noncurrent Assets [Member]
Assets, Long-term [Abstract]
Trading securities	31	34
Other investments	0	0
Fair Value, Recurring \| Significant Other Observable Inputs (Level 2)
Assets, Long-term [Abstract]
Total assets measured at fair value	54	48
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	$ 5	$ 5
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Liabilities, Long-term [Abstract]
Total liabilities measured at fair value	$ 36	$ 39
Fair Value, Recurring \| Significant Other Observable Inputs (Level 2) \| Other Current Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	0	0
Fair Value, Recurring \| Significant Other Observable Inputs (Level 2) \| Other Noncurrent Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	0	0
Deferred compensation liability	31	34
Fair Value, Recurring \| Significant Other Observable Inputs (Level 2) \| Other Current Assets [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	31	9
Short-term Investments		8
Fair Value, Recurring \| Significant Other Observable Inputs (Level 2) \| Other Noncurrent Assets [Member]
Assets, Long-term [Abstract]
Trading securities	0	0
Other investments	23	31
Fair Value, Recurring \| Significant Unobservable Inputs (Level 3)
Assets, Long-term [Abstract]
Total assets measured at fair value	0	0
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	$ 0	$ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Liabilities, Long-term [Abstract]
Contingent Consideration	$ 67
Total liabilities measured at fair value		$ 89
Fair Value, Recurring \| Significant Unobservable Inputs (Level 3) \| Other Current Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	66	62
Fair Value, Recurring \| Significant Unobservable Inputs (Level 3) \| Other Noncurrent Liabilities
Liabilities, Long-term [Abstract]
Contingent Consideration	1	27
Deferred compensation liability	0	0
Fair Value, Recurring \| Significant Unobservable Inputs (Level 3) \| Other Current Assets [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Short-term Investments		0
Fair Value, Recurring \| Significant Unobservable Inputs (Level 3) \| Other Noncurrent Assets [Member]
Assets, Long-term [Abstract]
Trading securities	0	0
Other investments	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Conti

FAIR VALUE MEASUREMENTS - Contingent Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 67	$ 89	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	3	110
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	(25)	(21)	$ 0
Fair Value, Recurring \| Other Current Liabilities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	66	62
Fair Value, Recurring \| Other Noncurrent Liabilities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	1	27
Significant Unobservable Inputs (Level 3) \| Fair Value, Recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	67
Significant Unobservable Inputs (Level 3) \| Fair Value, Recurring \| Other Current Liabilities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	66	62
Significant Unobservable Inputs (Level 3) \| Fair Value, Recurring \| Other Noncurrent Liabilities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 1	$ 27
Resolution Bioscience, Inc.
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration arrangements does not exceed	2 years 2 months 12 days
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 145
Resolution Bioscience, Inc. \| Significant Unobservable Inputs (Level 3) \| Fair Value, Recurring \| Revenue Component
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 0

FAIR VALUE MEASUREMENTS FAIR VA

FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of long-lived asset		$ 2	$ 98
Long-lived assets held for use impairment	$ 0	2	98
Fair value of assets, nonrecurring		0	0
Long lived assets held for sale Impairment	0	0	0
Impairments in non-marketable securities without readily determinable fair value	0	0	0
Carrying amount of non-marketable equity securities without readily determinable fair values	141	120
Net unrealized gains on our equity securities with RDFV	$ (78)	$ 92	$ 27

FAIR VALUE MEASUREMENTS - Non m

FAIR VALUE MEASUREMENTS - Non marketable securities (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	$ 6	$ 17	$ 27
Equity investments - without readily determinable fair value	141	120
Impairments in non-marketable securities without readily determinable fair value	0	0	$ 0
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount	35	29
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount	$ 0	$ 0

DERIVATIVES (Details)

DERIVATIVES (Details) - USD ($) $ in Millions	Sep. 06, 2019	Sep. 15, 2016	Oct. 31, 2022	Aug. 01, 2019	Feb. 01, 2016
Derivative Contracts [Abstract]
Aggregate fair value , net liability position			$ 1
Senior Notes 2026 \| Treasury Lock \| Cash Flow Hedges
Derivative Contracts [Abstract]
Derivative, Notional Amount					$ 300
Interest rate swap payments		$ 10
Remaining gain loss to be amortized on derivative			4
Senior Notes 2029 \| Treasury Lock
Derivative Contracts [Abstract]
Derivative, Notional Amount				$ 250
Interest rate swap payments	$ 6
Remaining gain loss to be amortized on derivative			$ 4

DERIVATIVES, Disclosures and de

DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) - Forward Contracts Buy/(Sell)	Oct. 31, 2022 USD ($) contracts
Designated as Hedging Instrument \| Cash Flow Hedges
Derivative [Line Items]
Number of Foreign Currency Derivatives Held \| contracts	270
Designated as Hedging Instrument \| Cash Flow Hedges \| Buy \| Singapore, Dollars
Derivative [Line Items]
Derivative, Notional Amount	$ 19,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Buy \| Other Currency
Derivative [Line Items]
Derivative, Notional Amount	4,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell
Derivative [Line Items]
Derivative, Notional Amount	446,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Euro
Derivative [Line Items]
Derivative, Notional Amount	78,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| British Pounds
Derivative [Line Items]
Derivative, Notional Amount	66,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Canadian Dollars
Derivative [Line Items]
Derivative, Notional Amount	55,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Japanese Yen
Derivative [Line Items]
Derivative, Notional Amount	93,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Korean Won
Derivative [Line Items]
Derivative, Notional Amount	90,000,000
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| China, Yuan Renminbi
Derivative [Line Items]
Derivative, Notional Amount	$ 87,000,000
Designated as Hedging Instrument \| Net Investment Hedging
Derivative [Line Items]
Number of Foreign Currency Derivatives Held	3
Designated as Hedging Instrument \| Net Investment Hedging \| Sell
Derivative [Line Items]
Derivative, Notional Amount	$ 10,000,000
Designated as Hedging Instrument \| Net Investment Hedging \| Sell \| Euro
Derivative [Line Items]
Derivative, Notional Amount	$ 10,000,000
Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Number of Foreign Currency Derivatives Held \| contracts	190
Derivatives Not Designated as Hedging Instruments \| Buy \| British Pounds
Derivative [Line Items]
Derivative, Notional Amount	$ 13,000,000
Derivatives Not Designated as Hedging Instruments \| Buy \| Danish Krone
Derivative [Line Items]
Derivative, Notional Amount	25,000,000
Derivatives Not Designated as Hedging Instruments \| Buy \| Singapore, Dollars
Derivative [Line Items]
Derivative, Notional Amount	24,000,000
Derivatives Not Designated as Hedging Instruments \| Buy \| Other Currency
Derivative [Line Items]
Derivative, Notional Amount	3,000,000
Derivatives Not Designated as Hedging Instruments \| Sell
Derivative [Line Items]
Derivative, Notional Amount	162,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| Euro
Derivative [Line Items]
Derivative, Notional Amount	18,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| Canadian Dollars
Derivative [Line Items]
Derivative, Notional Amount	17,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| Japanese Yen
Derivative [Line Items]
Derivative, Notional Amount	42,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| Korean Won
Derivative [Line Items]
Derivative, Notional Amount	10,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| Swiss Franc
Derivative [Line Items]
Derivative, Notional Amount	13,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| China, Yuan Renminbi
Derivative [Line Items]
Derivative, Notional Amount	100,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| Taiwan, New Dollars
Derivative [Line Items]
Derivative, Notional Amount	16,000,000
Derivatives Not Designated as Hedging Instruments \| Sell \| India, Rupees
Derivative [Line Items]
Derivative, Notional Amount	$ 11,000,000

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	$ 31	$ 9
Derivative Liability, Fair Value	5	5
Derivatives Not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Other Current Assets [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	8	3
Derivatives Not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Accrued Liabilities [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Liability, Fair Value	3	3
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts \| Other Current Assets [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	23	6
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts \| Accrued Liabilities [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Liability, Fair Value	$ 2	$ 2

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Gain (loss) recognized in other income (expense), net within continuing operations	$ 10	$ 0	$ (1)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (expense), net	Other income (expense), net	Other income (expense), net
Cash Flow Hedges
Derivative [Line Items]
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months	$ 24
Cash Flow Hedges \| Cost of Sales [Member]
Derivative [Line Items]
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months	20
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts
Derivative [Line Items]
Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales	36	$ (16)	$ (1)
Gain (loss) recognized in other income (expense), net within continuing operations	$ 0	$ 0	$ 2
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of revenue	Cost of revenue	Cost of revenue
Derivative Instrument, Gain Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]	Costs and Expenses	Costs and Expenses	Costs and Expenses
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts \| Accumulated Other Comprehensive Loss
Derivative [Line Items]
Other comprehensive income (loss) before reclassifications	$ 56	$ 2	$ (12)
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts \| Interest Expense
Derivative [Line Items]
Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net	(2)	(1)	(1)
Net Investment Hedging \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts
Derivative [Line Items]
Gain (loss) recognized in other income (expense), net within continuing operations	$ 0	$ 1	$ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (expense), net	Other income (expense), net	Other income (expense), net
Net Investment Hedging \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts \| Accumulated Other Comprehensive Loss
Derivative [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	$ 5	$ 1	$ (5)

RETIREMENT PLANS AND POST RETIE

RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details) - Deferred Profit Sharing - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	$ 93	$ 136
Projected Benefit Obligation	$ 93	$ 136

RETIREMENT PLANS AND POST RET_3

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Defined Contribution Plan Disclosure [Line Items]
Maximum employer matching contribution in the 401(k) plan (in hundredths)	6%
Maximum employee contribution to 401(k)	50%
401(k) Plan employer expense	$ 46	$ 43	$ 41
401(k) Additional company contribution
Defined Contribution Plan Disclosure [Line Items]
Transitional company contribution to employee 401(k)	4%
401(k) Additional company contribution \| 3 Percent
Defined Contribution Plan Disclosure [Line Items]
Transitional company contribution to employee 401(k)	3%
401(k) Additional company contribution \| 5 Percent
Defined Contribution Plan Disclosure [Line Items]
Transitional company contribution to employee 401(k)	5%

RETIREMENT PLANS AND POST RET_4

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Amortization of net actuarial gain (loss)	$ 28	$ 64
Amortization of prior service benefit	(1)	1
Pension Plan \| UNITED STATES
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	0	0	$ 0
Interest cost on benefit obligation	14	14	15
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(27)	(29)	(28)
Amortization of actuarial gain (loss)	0	4	3
Amortization of prior service benefit	0	0	0
Total periodic benefit cost (benefit)	(13)	(11)	(10)
Curtaliment and settlement	(4)	(1)	(4)
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	16	(92)	26
Amortization of net actuarial gain (loss)	0	(4)	(3)
Amortization of prior service benefit	0	0	0
Settlement and Curtailment Gain (Loss), before Tax	(4)	(1)	(4)
Foreign Currency	0	0	0
Total recognized in other comprehensive (income) loss	12	(97)	19
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	3	(107)	13
Pension Plan \| Foreign Plan
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	22	22	24
Interest cost on benefit obligation	9	8	8
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(43)	(49)	(47)
Amortization of actuarial gain (loss)	25	53	49
Amortization of prior service benefit	0	0	0
Total periodic benefit cost (benefit)	13	34	34
Curtaliment and settlement	0	0	0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	(83)	(114)	20
Amortization of net actuarial gain (loss)	(25)	(53)	(49)
Amortization of prior service benefit	0	0	0
Settlement and Curtailment Gain (Loss), before Tax	0	0	0
Foreign Currency	11	5	10
Total recognized in other comprehensive (income) loss	(97)	(162)	(19)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	(84)	(128)	15
Post-Retirement Benefit Plan \| UNITED STATES
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	1	1	1
Interest cost on benefit obligation	2	2	3
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(6)	(6)	(7)
Amortization of actuarial gain (loss)	(2)	4	4
Amortization of prior service benefit	(1)	(1)	(7)
Total periodic benefit cost (benefit)	(6)	0	(6)
Curtaliment and settlement	0	0	0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	15	(30)	5
Amortization of net actuarial gain (loss)	2	(4)	(4)
Amortization of prior service benefit	1	1	7
Settlement and Curtailment Gain (Loss), before Tax	0	0	0
Foreign Currency	0	0	0
Total recognized in other comprehensive (income) loss	18	(33)	8
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	$ 12	$ (33)	$ 2

RETIREMENT PLANS AND POST RET_5

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Change in benefit obligation: [Roll Forward]
Actuarial gain (loss)	$ 412	$ (9)
Foreign Plan \| Pension Plan
Change in fair value of plan assets: [Roll Forward]
Fair Value Balance, beginning of year	1,093	945
Actual return on plan assets	(147)	160
Employer contributions	17	19
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	1	1
Benefits paid	35	31
Settlements	0	0
Currency impact	(181)	(1)
Fair Value Balance, end of year	748	1,093	$ 945
Change in benefit obligation: [Roll Forward]
Benefit Obligation Balance, Beginning of year	1,100	1,094
Service cost	22	22	24
Interest cost	9	8	8
Participant's contributions	1	1
Actuarial gain (loss)	(262)	2
Benefits paid	35	31
Settlement	0	0
Currency impact	(170)	4
Benefit Obligation Balance, end of year	665	1,100	1,094
Funded status of plan [Abstract]
Funded status of plan	83	(7)
Actuarial (gains) losses	52	149
Prior service costs (benefits)	0	0
Total	52	149
UNITED STATES \| Pension Plan
Change in fair value of plan assets: [Roll Forward]
Fair Value Balance, beginning of year	551	439
Actual return on plan assets	(122)	138
Employer contributions	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Benefits paid	10	8
Settlements	(23)	(18)
Currency impact	0	0
Fair Value Balance, end of year	396	551	439
Change in benefit obligation: [Roll Forward]
Benefit Obligation Balance, Beginning of year	512	510
Service cost	0	0	0
Interest cost	14	14	15
Participant's contributions	0	0
Actuarial gain (loss)	(133)	15
Benefits paid	10	8
Settlement	(26)	(19)
Currency impact	0	0
Benefit Obligation Balance, end of year	357	512	510
Funded status of plan [Abstract]
Funded status of plan	39	39
Actuarial (gains) losses	48	36
Prior service costs (benefits)	0	0
Total	48	36
UNITED STATES \| Post-Retirement Benefit Plan
Change in fair value of plan assets: [Roll Forward]
Fair Value Balance, beginning of year	116	93
Actual return on plan assets	(26)	28
Employer contributions	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Benefits paid	5	5
Settlements	0	0
Currency impact	0	0
Fair Value Balance, end of year	85	116	93
Change in benefit obligation: [Roll Forward]
Benefit Obligation Balance, Beginning of year	84	94
Service cost	1	1	1
Interest cost	2	2	3
Participant's contributions	0	0
Actuarial gain (loss)	(17)	(8)
Benefits paid	5	5
Settlement	0	0
Currency impact	0	0
Benefit Obligation Balance, end of year	65	84	$ 94
Funded status of plan [Abstract]
Funded status of plan	20	32
Actuarial (gains) losses	(6)	(23)
Prior service costs (benefits)	(3)	(4)
Total	(9)	(27)
Other Assets \| Foreign Plan \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	140	160
Other Assets \| UNITED STATES \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	42	46
Other Assets \| UNITED STATES \| Post-Retirement Benefit Plan
Funded status of plan [Abstract]
Funded status of plan	20	32
Employee compensation and benefits [Member] \| Foreign Plan \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	0	0
Employee compensation and benefits [Member] \| UNITED STATES \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	(1)	(1)
Employee compensation and benefits [Member] \| UNITED STATES \| Post-Retirement Benefit Plan
Funded status of plan [Abstract]
Funded status of plan	0	0
Retirement and post-retirement benefits \| Foreign Plan \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	(57)	(167)
Retirement and post-retirement benefits \| UNITED STATES \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	(2)	(6)
Retirement and post-retirement benefits \| UNITED STATES \| Post-Retirement Benefit Plan
Funded status of plan [Abstract]
Funded status of plan	$ 0	$ 0

RETIREMENT PLANS AND POST RET_6

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Pension Plan \| Foreign Plan
Amounts recognized in the consolidated balance sheet
Funded status of plan	$ 83	$ (7)
Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract]
Actuarial (gains) losses	52	149
Prior service costs (benefits)	0	0
Total	52	149
Pension Plan \| Foreign Plan \| Other Assets
Amounts recognized in the consolidated balance sheet
Funded status of plan	140	160
Pension Plan \| Foreign Plan \| Employee compensation and benefits [Member]
Amounts recognized in the consolidated balance sheet
Funded status of plan	0	0
Pension Plan \| Foreign Plan \| Retirement and post-retirement benefits
Amounts recognized in the consolidated balance sheet
Funded status of plan	(57)	(167)
Pension Plan \| UNITED STATES
Amounts recognized in the consolidated balance sheet
Funded status of plan	39	39
Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract]
Actuarial (gains) losses	48	36
Prior service costs (benefits)	0	0
Total	48	36
Pension Plan \| UNITED STATES \| Other Assets
Amounts recognized in the consolidated balance sheet
Funded status of plan	42	46
Pension Plan \| UNITED STATES \| Employee compensation and benefits [Member]
Amounts recognized in the consolidated balance sheet
Funded status of plan	(1)	(1)
Pension Plan \| UNITED STATES \| Retirement and post-retirement benefits
Amounts recognized in the consolidated balance sheet
Funded status of plan	(2)	(6)
Post-Retirement Benefit Plan \| UNITED STATES
Amounts recognized in the consolidated balance sheet
Funded status of plan	20	32
Amounts Recognized in Accumulated Other Comprehensive Income (loss): [Abstract]
Actuarial (gains) losses	(6)	(23)
Prior service costs (benefits)	(3)	(4)
Total	(9)	(27)
Post-Retirement Benefit Plan \| UNITED STATES \| Other Assets
Amounts recognized in the consolidated balance sheet
Funded status of plan	20	32
Post-Retirement Benefit Plan \| UNITED STATES \| Employee compensation and benefits [Member]
Amounts recognized in the consolidated balance sheet
Funded status of plan	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Retirement and post-retirement benefits
Amounts recognized in the consolidated balance sheet
Funded status of plan	$ 0	$ 0

RETIREMENT PLANS AND POST RET_7

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details)	Oct. 31, 2022
Foreign Plan \| Pension Plan \| Minimum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	15%
Foreign Plan \| Pension Plan \| Minimum \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	30%
Foreign Plan \| Pension Plan \| Minimum \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	0%
Foreign Plan \| Pension Plan \| Minimum \| Other Contract
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	0%
Foreign Plan \| Pension Plan \| Maximum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	60%
Foreign Plan \| Pension Plan \| Maximum \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	80%
Foreign Plan \| Pension Plan \| Maximum \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	25%
Foreign Plan \| Pension Plan \| Maximum \| Other Contract
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	55%
UNITED STATES \| Deferred Profit Sharing \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	60%
UNITED STATES \| Deferred Profit Sharing \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	40%
UNITED STATES \| Pension Plan \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	50%
UNITED STATES \| Pension Plan \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	50%
UNITED STATES \| Pension Plan \| Other Investments
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments	1%
UNITED STATES \| Other Postretirement Benefits Plan \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	50%
UNITED STATES \| Other Postretirement Benefits Plan \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	50%
UNITED STATES \| Other Postretirement Benefits Plan \| Other Investments
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments	1%

RETIREMENT PLANS AND POST RET_8

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Pension Plan \| Foreign Plan
Fair value of plan assets [Abstract]
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets	$ 172	$ 691
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets.	114	524
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(181)	(1)
Projected benefit obligation and fair value of plan assets [Abstract]
Total projected benefit obligation - aggregate benefit obligation	665	1,100
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation	493	409
Fair Value of plan assets where fair value exceeds pension benefit obligation	634	569
Benefit Obligation	665	1,100	$ 1,094
Accumulated benefit obligation and fair value of plan assets
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	167	668
Total accumulated benefit obligation - aggregate benefit obligation	652	1,068
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	114	524
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO	485	400
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO.	634	569
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	16
Fair Value of Plan Assets	748	1,093	945
Net asset value excluded from fair value by input	189	284
Pension Plan \| Foreign Plan \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	22	25
Net asset value excluded from fair value by input	0	1
Pension Plan \| Foreign Plan \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	360	543
Net asset value excluded from fair value by input	96	151
Pension Plan \| Foreign Plan \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	274	525
Net asset value excluded from fair value by input	93	132
Pension Plan \| Foreign Plan \| Other Contract
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	92
Net asset value excluded from fair value by input	0
Pension Plan \| Foreign Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	347	531
Pension Plan \| Foreign Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| Foreign Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	264	380
Pension Plan \| Foreign Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	83	151
Pension Plan \| Foreign Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other Contract
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0
Pension Plan \| Foreign Plan \| Significant Unobservable Inputs (Level 3)
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Realized gains/(losses)	0	0
Unrealized gains/(losses)	39	0
Purchases, sales, issuances, and settlements	(5)	0
Transfers in (out)	159	0
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(23)	0
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	92	0	0
Pension Plan \| Foreign Plan \| Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| Foreign Plan \| Significant Unobservable Inputs (Level 3) \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| Foreign Plan \| Significant Unobservable Inputs (Level 3) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| Foreign Plan \| Significant Unobservable Inputs (Level 3) \| Other Contract
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	92
Pension Plan \| Foreign Plan \| Significant Other Observable Inputs (Level 2)
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	120	278
Pension Plan \| Foreign Plan \| Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	22	24
Pension Plan \| Foreign Plan \| Significant Other Observable Inputs (Level 2) \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	12
Pension Plan \| Foreign Plan \| Significant Other Observable Inputs (Level 2) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	98	242
Pension Plan \| Foreign Plan \| Significant Other Observable Inputs (Level 2) \| Other Contract
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0
Pension Plan \| UNITED STATES
Fair value of plan assets [Abstract]
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets	3	7
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets.	0	0
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0	0
Projected benefit obligation and fair value of plan assets [Abstract]
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation	354	505
Fair Value of plan assets where fair value exceeds pension benefit obligation	396	551
Benefit Obligation	357	512	510
Accumulated benefit obligation and fair value of plan assets
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	3	7
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	0	0
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO	354	505
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO.	396	551
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	0
Fair Value of Plan Assets	396	551	439
Net asset value excluded from fair value by input	345	485
Assets for Plan Benefits, Defined Benefit Plan	396
Pension Plan \| UNITED STATES \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	1	2
Net asset value excluded from fair value by input	1	2
Pension Plan \| UNITED STATES \| Equity Securities
Accumulated benefit obligation and fair value of plan assets
Net asset value excluded from fair value by input		214
Pension Plan \| UNITED STATES \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	194	276
Net asset value excluded from fair value by input	145
Pension Plan \| UNITED STATES \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	199	271
Net asset value excluded from fair value by input	199	269
Pension Plan \| UNITED STATES \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	2	2
Net asset value excluded from fair value by input	0	0
Pension Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets		64
Assets for Plan Benefits, Defined Benefit Plan	49
Pension Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	49	62
Pension Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	2
Pension Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3)
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Realized gains/(losses)	0	1
Unrealized gains/(losses)	0	0
Purchases, sales, issuances, and settlements	0	(1)
Transfers in (out)	0	0
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	2	2	2
Assets for Plan Benefits, Defined Benefit Plan	2
Pension Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets		0
Pension Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0
Pension Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	2	2
Pension Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2)
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets		0
Assets for Plan Benefits, Defined Benefit Plan	0
Pension Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets		0
Pension Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Defined Benefit Plan, Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0
Pension Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Pension Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0	0
Projected benefit obligation and fair value of plan assets [Abstract]
Benefit Obligation	65	84	94
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	85	116	93
Net asset value excluded from fair value by input	74	102
Post-Retirement Benefit Plan \| UNITED STATES \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	3
Net asset value excluded from fair value by input	0	3
Post-Retirement Benefit Plan \| UNITED STATES \| Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	42	55
Net asset value excluded from fair value by input	32	42
Post-Retirement Benefit Plan \| UNITED STATES \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	42	57
Net asset value excluded from fair value by input	42	57
Post-Retirement Benefit Plan \| UNITED STATES \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	1	1
Net asset value excluded from fair value by input	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	10	13
Post-Retirement Benefit Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	10	13
Post-Retirement Benefit Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3)
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Realized gains/(losses)	0	1
Unrealized gains/(losses)	0	0
Purchases, sales, issuances, and settlements	0	(1)
Transfers in (out)	0	0
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	1	1	$ 1
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Unobservable Inputs (Level 3) \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	1	1
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2)
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Equity Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Fixed Income Securities
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	0	0
Post-Retirement Benefit Plan \| UNITED STATES \| Significant Other Observable Inputs (Level 2) \| Other Investments
Accumulated benefit obligation and fair value of plan assets
Fair Value of Plan Assets	$ 0	$ 0

RETIREMENT PLANS AND POST RET_9

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details) $ in Millions	Oct. 31, 2022 USD ($)
Pension Plan \| Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	$ 16
Future benefit payments [Abstract]
2022	32
2023	33
2024	34
2025	34
2026	35
2027 - 2031	187
Pension Plan \| UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	0
Future benefit payments [Abstract]
2022	31
2023	34
2024	32
2025	32
2026	32
2027 - 2031	142
Post-Retirement Benefit Plan \| UNITED STATES
Future benefit payments [Abstract]
2022	6
2023	6
2024	7
2025	7
2026	7
2027 - 2031	34
Other Postretirement Benefits Plan \| UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	$ 0

RETIREMENT PLANS AND POST RE_10

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details)	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Foreign Plan \| Pension Plan \| Minimum
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	0.29%	0.07%	0.22%
Average increase in compensation levels (in hundredths)	2%	2%	2.25%
Expected long-term return on assets (in hundredths)	2.75%	4%	4%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate	0.30%	0.10%	0%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	1.50%	0.29%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	2%	2%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate	0.50%	0.30%
Foreign Plan \| Pension Plan \| Maximum
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	1.76%	1.54%	1.81%
Average increase in compensation levels (in hundredths)	3.50%	3%	3%
Expected long-term return on assets (in hundredths)	5.50%	5.50%	5.75%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate	0.50%	0.50%	0.75%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	4.77%	1.76%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	3.25%	3.50%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate	2.10%	0.50%
UNITED STATES \| Pension Plan
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	2.75%	2.75%	3.25%
Expected long-term return on assets (in hundredths)	5%	7%	7%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	6%	2.75%
UNITED STATES \| Post-Retirement Benefit Plan
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	2.75%	2.50%	3%
Expected long-term return on assets (in hundredths)	5%	7%	7%
Current medical cost trend rate	6%	6.25%	6.25%
Ultimate medical cost trend rate	4.50%	4.50%	4.50%
Medical cost trend rate decreases to ultimate rate in year	2027	2029	2029
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	6%	2.75%
Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year	7%	6%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	4.75%	4.50%
defined benefit plan, year health care cost trend rate reaches ultimate trend	2029	2027

GUARANTEES (Details)

GUARANTEES (Details) - USD ($) $ in Millions	12 Months Ended
GUARANTEES (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Summary of standard warranty accrual activity
Beginning balance	$ 30	$ 32
Accruals for warranties including change in estimates	50	52
Settlements made during the period	(50)	(54)
Ending balance	30	30
Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]
Accruals for warranties due within one year	30	29
Accruals for warranties due after one year	0	1
Bank Guarantees	$ 37	$ 46

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions	Oct. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Other Purchase Commitments	$ 139

SHORT-TERM DEBT - Credit Facili

SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details) - Line of Credit - USD ($) $ in Millions		12 Months Ended
	Mar. 13, 2019	Oct. 31, 2022	Oct. 31, 2021	Apr. 21, 2021	May 26, 2020
5 yr unsecured credit facility
Line of Credit Facility [Abstract]
Credit facility initiation date	Mar. 13, 2019
Line of credit facility expiration date	Mar. 13, 2024
Maximum borrowing capacity	$ 1,000			$ 1,350
Short-term debt terms (years)		five
Outstanding balance		$ 0	$ 0
Additional Incremental Term Loan Facility
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 500			$ 500
Outstanding balance		0	0
Commercial Paper
Line of Credit Facility [Abstract]
Maximum borrowing capacity					$ 1,350
Outstanding balance		$ 35	$ 0
Short-term Debt, Weighted Average Interest Rate, at Point in Time		3.54%

LONG-TERM DEBT - Carrying Value

LONG-TERM DEBT - Carrying Value (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Debt Instrument [Line Items]
Long-Term Debt	$ 2,733	$ 2,729
Senior Notes 2023 [Member]
Debt Instrument [Line Items]
Long-Term Debt	0	599
Senior Notes 2026
Debt Instrument [Line Items]
Long-Term Debt	299	298
Senior Notes 2029
Debt Instrument [Line Items]
Long-Term Debt	495	494
Senior Notes 2030 [Member]
Debt Instrument [Line Items]
Long-Term Debt	496	496
Senior Notes 2031
Debt Instrument [Line Items]
Long-Term Debt	843	842
Senior Notes
Debt Instrument [Line Items]
Long-Term Debt	2,133	$ 2,729
Term Loan Maturing 2025
Debt Instrument [Line Items]
Long-Term Debt	$ 600

LONG-TERM DEBT - Senior Notes (

LONG-TERM DEBT - Senior Notes (Details) - USD ($) $ in Millions

12 Months Ended

May 04, 2022

Mar. 12, 2021

Jun. 04, 2020

Sep. 16, 2019

Sep. 22, 2016

Jun. 21, 2013

Oct. 31, 2022

Oct. 31, 2021

Oct. 31, 2020

Aug. 01, 2019

Sep. 15, 2016

Feb. 01, 2016

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 9

$ 17

$ 0

Early Repayment of Senior Debt

609

$ 417

$ 0

Senior Notes 2023 [Member]

Debt Instrument [Line Items]

Issuance date of debt

Jun. 21, 2013

Aggregate face amount of debt

$ 600

Issue rate percentage of principal amount

99.544%

Maturity date

Jul. 15, 2023

Fixed interest rate per annum (in hundredths)

3.875%

Interest payment frequency

semi-annually

Date payments commenced

Jan. 15, 2014

Repayments of senior debt

$ 609

Loss on extinguishment of debt

Early Repayment of Senior Debt

600

Debt Instrument, Increase, Accrued Interest

$ 7

Senior Notes 2026

Debt Instrument [Line Items]

Issuance date of debt

Sep. 22, 2016

Aggregate face amount of debt

$ 300

Issue rate percentage of principal amount

99.624%

Maturity date

Sep. 22, 2026

Fixed interest rate per annum (in hundredths)

3.05%

Interest payment frequency

semi-annually

Date payments commenced

Mar. 22, 2017

Senior Notes 2029

Debt Instrument [Line Items]

Issuance date of debt

Sep. 16, 2019

Aggregate face amount of debt

$ 500

Issue rate percentage of principal amount

99.316%

Maturity date

Sep. 15, 2029

Fixed interest rate per annum (in hundredths)

2.75%

Interest payment frequency

semi-annually

Date payments commenced

Mar. 15, 2020

Senior Notes 2030 [Member]

Debt Instrument [Line Items]

Issuance date of debt

Jun. 04, 2020

Aggregate face amount of debt

$ 500

Issue rate percentage of principal amount

99.812%

Maturity date

Jun. 04, 2030

Fixed interest rate per annum (in hundredths)

2.10%

Interest payment frequency

semi-annually

Date payments commenced

Dec. 04, 2020

Senior Notes 2031

Debt Instrument [Line Items]

Issuance date of debt

Mar. 12, 2021

Aggregate face amount of debt

$ 850

Issue rate percentage of principal amount

99.822%

Maturity date

Mar. 12, 2031

Fixed interest rate per annum (in hundredths)

2.30%

Date payments commenced

Sep. 12, 2021

Treasury Lock | Senior Notes 2029

Debt Instrument [Line Items]

Derivative, Notional Amount

$ 250

Remaining gain loss to be amortized on derivative

Treasury Lock | Senior Notes 2026 | Cash Flow Hedges

Debt Instrument [Line Items]

Derivative, Notional Amount

$ 300

Remaining gain loss to be amortized on derivative

$ 4

Interest Rate Swap

$ 300

Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives

$ 10

LONG-TERM DEBT - Term Loan (Det

LONG-TERM DEBT - Term Loan (Details) - USD ($) $ in Millions	Oct. 31, 2022	Apr. 15, 2022	Oct. 31, 2021
Line of Credit Facility [Line Items]
Long-Term Debt	$ 2,733		$ 2,729
Term Loan Maturing 2025
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 600
Long-Term Debt	$ 600
Long-Term Debt, Weighted Average Interest Rate, at Point in Time	3.98%

STOCKHOLDERS' EQUITY Stock Repu

STOCKHOLDERS' EQUITY Stock Repurchases (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Feb. 18, 2021	Nov. 19, 2018
2019 Repurchase Program [Member]
Share Repurchase Program [Line Items]
Stock Repurchase Program, Authorized Amount					$ 1,750
Stock Repurchased and Retired During Period, Shares		3.1	5.2
Stock Repurchased and Retired During Period, Value		$ 365	$ 469
Remaining authorized repurchase amount				$ 193
2021 Repurchase Program
Share Repurchase Program [Line Items]
Stock Repurchase Program, Authorized Amount				$ 2,000
Stock Repurchased and Retired During Period, Shares	8.4	3
Stock Repurchased and Retired During Period, Value	$ 1,139	$ 423
Remaining authorized repurchase amount	438
Retained Earnings
Share Repurchase Program [Line Items]
Stock Repurchased and Retired During Period, Value	1,028	707	398
Additional Paid-in Capital
Share Repurchase Program [Line Items]
Stock Repurchased and Retired During Period, Value	$ 111	$ 81	$ 71

STOCKHOLDERS' EQUITY STOCKHOLDE

STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Nov. 16, 2022	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Dividends [Abstract]
Cash Dividends Declared (per common share)		$ 0.840	$ 0.776	$ 0.720
Cash dividends declared		$ 250	$ 236	$ 222
Aggregate cash dividends paid		$ 250	$ 236	$ 222
Subsequent Event
Dividends [Abstract]
Cash Dividends Declared (per common share)	$ 0.225
Cash dividends declared	$ 66
Dividends Payable, Date Declared	Nov. 16, 2022
Dividends payment date	Jan. 25, 2023
Dividends date of record	Jan. 03, 2023

STOCKHOLDERS' EQUITY -Accumulat

STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Foreign currency translation, net of tax expense of $4 and $(8)	$ (335)	$ (185)
Foreign currency translation, tax	4	(8)
Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $71 and $80	(32)	(100)
Unrealized losses on defined benefit plans, tax	71	80
Unrealized gains (losses) on derivative instruments, net of tax (expense) benefit of $(4) and $1	20	3
Unrealized gains (losses) on derivative instruments, tax	(4)	1
Accumulated other comprehensive loss	$ (347)	$ (282)	$ (522)

STOCKHOLDERS' EQUITY - Changes

STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Beginning Balance	$ (282)	$ (522)
Other comprehensive income (loss) before reclassifications	(56)	241
Amounts reclassified out of accumulated other comprehensive income (loss)	(7)	80
Tax (expense) benefit	(2)	(81)
Other Comprehensive Income (Loss)	(65)	240	$ (8)
Ending Balance	(347)	(282)	(522)
Foreign Currency Translation
Beginning Balance	(185)	(194)
Other comprehensive income (loss) before reclassifications	(162)	11
Amounts reclassified out of accumulated other comprehensive income (loss)	0	0
Tax (expense) benefit	12	(2)
Other Comprehensive Income (Loss)	(150)	9
Ending Balance	(335)	(185)	(194)
Prior Service Credits
Beginning Balance	124	125
Other comprehensive income (loss) before reclassifications	0	0
Amounts reclassified out of accumulated other comprehensive income (loss)	(1)	(1)
Tax (expense) benefit	0	0
Other Comprehensive Income (Loss)	(1)	(1)
Ending Balance	123	124	125
Actuarial Losses
Beginning Balance	(224)	(442)
Other comprehensive income (loss) before reclassifications	50	228
Amounts reclassified out of accumulated other comprehensive income (loss)	28	64
Tax (expense) benefit	(9)	(74)
Other Comprehensive Income (Loss)	69	218
Ending Balance	(155)	(224)	(442)
Unrealized Gains (Losses) on Derivatives
Beginning Balance	3	(11)
Other comprehensive income (loss) before reclassifications	56	2
Amounts reclassified out of accumulated other comprehensive income (loss)	(34)	17
Tax (expense) benefit	(5)	(5)
Other Comprehensive Income (Loss)	17	14
Ending Balance	$ 20	$ 3	$ (11)

STOCKHOLDERS' EQUITY - Reclassi

STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Unrealized gains (losses) on derivatives	$ 34	$ (17)
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit)	(8)	4	$ 0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	26	(13)	$ (2)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax	(28)	(64)
Amortization of prior service benefit	1	(1)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax	(27)	(63)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax	7	15
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax	(20)	(48)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	6	(61)
Cost of Product and Services
Unrealized gains (losses) on derivatives	36	(16)
Interest Expense
Unrealized gains (losses) on derivatives	$ (2)	$ (1)

SEGMENT INFORMATION Profitabili

SEGMENT INFORMATION Profitability (Details) $ in Millions	12 Months Ended
SEGMENT INFORMATION Profitability (Details) $ in Millions	Oct. 31, 2022 USD ($) segment	Oct. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)
Segment Reporting [Abstract]
Number of operating segments \| segment	3
Select income statement components
Net revenue	$ 6,848	$ 6,319	$ 5,339
Income from operations	1,618	1,347	846
Depreciation expense	120	122	119
Share-based compensation	$ 125	$ 110	$ 83
Revenue Benchmark
Select income statement components
Percentage of revenue from a single customer	No customer represented 10 percent or more of our total net revenue	No customer represented 10 percent or more of our total net revenue	No customer represented 10 percent or more of our total net revenue
Life Sciences and Applied Markets
Select income statement components
Net revenue	$ 4,007	$ 3,663	$ 3,115
Income from operations	1,186	1,017	792
Depreciation expense	59	60	58
Share-based compensation	69	60	46
Diagnostics and Genomics
Select income statement components
Net revenue	1,389	1,296	1,047
Income from operations	301	273	192
Depreciation expense	39	39	39
Share-based compensation	25	22	17
Agilent CrossLab
Select income statement components
Net revenue	1,452	1,360	1,177
Income from operations	370	323	272
Depreciation expense	22	23	22
Share-based compensation	26	24	18
Segment Total
Select income statement components
Net revenue	6,848	6,319	5,339
Income from operations	1,857	1,613	1,256
Depreciation expense	120	122	119
Share-based compensation	$ 120	$ 106	$ 81

SEGMENT INFORMATION Reconciliat

SEGMENT INFORMATION Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Reconcilitation between statement results and enterprise results [Abstract]
Total reportable segment income from operations	$ 1,857	$ 1,613	$ 1,256
Amortization	(191)	(194)	(184)
Acquisition and integration costs	(25)	(41)	(41)
Transformational initiatives	(30)	(37)	(53)
Share-based Payment Arrangement, Accelerated Cost	0	(1)	(2)
Asset impairment charges	0	2	99
Business exit and divestiture costs	(7)	(5)	(2)
Change in fair value of contingent consideration	(25)	(21)	0
Special compliance costs	0	(1)	0
Other Nonrecurring Expense	11	6	29
Interest income	(9)	(2)	(8)
Interest Expense	(84)	(81)	(78)
Other income (expense), net	(39)	92	66
Income before taxes, as reported	$ 1,504	$ 1,360	$ 842

SEGMENT INFORMATION Segment Ass

SEGMENT INFORMATION Segment Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Segment Reporting Information [Line Items]
Segment Reporting Reconciliation Item Assets	$ 8,313	$ 7,900
Cash and cash equivalents	1,053	1,484	$ 1,441
Short-term Investments	0	91
Prepaid expenses	119	91
Long-term investments	195	185
Long term and other receivables	134	126
Deferred tax assets	259	280
Right-of-use asset	150	178
Other	322	341
Total assets	10,532	10,705
Capital expenditures	291	188	$ 119
Other Noncurrent Assets [Member]
Segment Reporting Information [Line Items]
Deferred tax assets	246	309
Life Sciences and Applied Markets
Segment Reporting Information [Line Items]
Total assets	3,955	3,741
Capital expenditures	77	64
Diagnostics and Genomics
Segment Reporting Information [Line Items]
Total assets	3,489	3,320
Capital expenditures	181	100
Agilent CrossLab
Segment Reporting Information [Line Items]
Total assets	869	839
Capital expenditures	33	24
Segment Total
Segment Reporting Information [Line Items]
Total assets	8,313	7,900
Capital expenditures	$ 291	$ 188

SEGMENT INFORMATION - Entity-Wi

SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Revenue by geography
Net revenue	$ 6,848	$ 6,319	$ 5,339
UNITED STATES
Revenue by geography
Net revenue	2,385	2,159	1,752
CHINA
Revenue by geography
Net revenue	1,499	1,273	1,087
Rest Of World
Revenue by geography
Net revenue	$ 2,964	$ 2,887	$ 2,500

SEGMENT INFORMATION - Entity-_2

SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details) - USD ($) $ in Millions	Oct. 31, 2022	Oct. 31, 2021
Segment Reporting Information [Line Items]
Long-Lived Assets	$ 1,723	$ 1,633
UNITED STATES
Segment Reporting Information [Line Items]
Long-Lived Assets	1,080	912
GERMANY
Segment Reporting Information [Line Items]
Long-Lived Assets	151	134
Rest Of World
Segment Reporting Information [Line Items]
Long-Lived Assets	$ 492	$ 587

Schedule II Valuation and Qua_2

Schedule II Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Movement in valuation and qualifying accounts [Roll Forward]
Balance at Beginning of Period	$ 120	$ 132	$ 134
Additions Charged to Expenses or Other Accounts	7	5	6
Deductions Credited to Expenses or Other Accounts	(12)	(17)	(8)
Balance at End of Period	$ 115	$ 120	$ 132